[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 193
1. Osime OC, Onunu AN: Some malignant tumours in HIV -infected individuals in Benin City Nigeria. Niger Postgrad Med J; 2007 Sep;14(3):195-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Some malignant tumours in HIV -infected individuals in Benin City Nigeria.
  • AIM AND OBJECTIVES: The aim of the study was to report the cases of some malignancies seen in Human Immune Deficiency Virus (HIV) - positive patients seen at the UBTH between January 1999 and December 2003.
  • PATIENTS AND METHODS: All patients that presented to the medical and surgical units of the UBTH within the period of the study and who had histologically confirmed malignant conditions and also tested to HIV were included in the study.
  • Of the patients that tested positive for HIV, Hodgkin's lymphoma was the commonest form of malignancy while leukaemia was the least common.
  • [MeSH-major] Lymphoma, AIDS-Related / epidemiology. Sarcoma, Kaposi / epidemiology


2. Del Valle L, Piña-Oviedo S: HIV disorders of the brain: pathology and pathogenesis. Front Biosci; 2006;11:718-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Approximately 16,000 new cases are diagnosed every day and almost 3 million people die every year from AIDS, making it the fourth leading cause of death in the world.
  • Since the introduction of highly active anti-retroviral therapy (HAART) in the mid 1990s, the morbidity and mortality associated with HIV-1 infection has significantly decreased and AIDS has become a chronic disorder.
  • However, neuropathological conditions associated with AIDS are still present in approximately 70 to 90% of patients and can be the result of HIV itself or of opportunistic infections.
  • Here we briefly review the pathology and pathophysiology of AIDS-Encephalopathy, of some of the significant opportunistic infections affecting the brain in the context of AIDS, including Progressive Multifocal Leukoencephalopathy (PML) a demyelinating disease caused by the human neurotropic JC virus, Toxoplasmosis, Cryptococcosis and of primary CNS lymphoma, a brain malignancy frequently associated with HIV-1 infection, all of them considered AIDS defining conditions.
  • [MeSH-major] AIDS-Related Opportunistic Infections / virology. Brain / virology. Brain Diseases / virology. HIV Infections / pathology


3. Chu K, Misinde D, Massaquoi M, Pasulani O, Mwagomba B, Ford N, Zachariah R: Risk factors for mortality in AIDS-associated Kaposi sarcoma in a primary care antiretroviral treatment program in Malawi. Int Health; 2010 Jun;2(2):99-102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for mortality in AIDS-associated Kaposi sarcoma in a primary care antiretroviral treatment program in Malawi.
  • AIDS-associated Kaposi sarcoma (AIDS-KS) is the most common HIV-related malignancy.
  • This retrospective cohort study describes characteristics of patients with AIDS-KS and factors associated with mortality in an antiretroviral treatment (ART) program in rural Malawi.
  • Of 11 122 patients enrolled on ART, 830 (7%) had AIDS-KS.
  • Patients with AIDS-KS were more likely to be lost to follow-up (22% versus 14%, P < 0.001) and showed a higher mortality (22% versus 10%, P < 0.001) compared to patients without AIDS-KS.
  • A CD4 count ≤150 cells/μl, advanced stage AIDS-KS, and absence of bleomycin chemotherapy were associated with increased mortality.
  • Earlier diagnosis and improved treatment of AIDS-KS are urgently needed in order to reduce mortality.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24037469.001).
  • [ISSN] 1876-3413
  • [Journal-full-title] International health
  • [ISO-abbreviation] Int Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


Advertisement
4. Davis DA, Singer KE, Reynolds IP, Haque M, Yarchoan R: Hypoxia enhances the phosphorylation and cytotoxicity of ganciclovir and zidovudine in Kaposi's sarcoma-associated herpesvirus infected cells. Cancer Res; 2007 Jul 15;67(14):7003-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypoxia enhances the phosphorylation and cytotoxicity of ganciclovir and zidovudine in Kaposi's sarcoma-associated herpesvirus infected cells.
  • Primary effusion lymphoma (PEL) is a rare B-cell lymphoma caused by Kaposi's sarcoma-associated herpesvirus (KSHV).
  • These findings may have clinical applicability in the development of effective therapies for PEL or other KSHV-related malignancies.

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ZIDOVUDINE .
  • Hazardous Substances Data Bank. GANCICLOVIR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17638913.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 4B9XT59T7S / Zidovudine; P9G3CKZ4P5 / Ganciclovir
  •  go-up   go-down


5. Gormley RH, Kovarik CL: Dermatologic manifestations of HPV in HIV-infected individuals. Curr HIV/AIDS Rep; 2009 Aug;6(3):130-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Anogenital HPV-related disease includes benign condyloma acuminata, the most common cutaneous manifestation of genital HPV infection; intermediate malignancy or premalignant conditions including giant condyloma acuminata (also called Buschke-Loewenstein tumor), anal intraepithelial neoplasia, penile intraepithelial neoplasia, and vaginal or vulvar intraepithelial neoplasia; and frankly malignant disease including Bowen's disease and invasive anal, penile, or vulvar carcinoma.
  • Cutaneous HPV-related disease in nongenital skin is also increased in HIV-positive patients, in the form of benign common warts, epidermodysplasia verruciformis-like skin lesions, and nonmelanoma skin cancers.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Oncol. 2007 Sep;19(5):470-5 [17762573.001]
  • [Cites] J Am Acad Dermatol. 2000 Aug;43(2 Pt 2):340-3 [10901717.001]
  • [Cites] Sex Transm Dis. 2004 Feb;31(2):96-9 [14743072.001]
  • [Cites] Int J STD AIDS. 1999 Dec;10(12):803-7 [10639061.001]
  • [Cites] Am J Obstet Gynecol. 2004 May;190(5):1241-8 [15167825.001]
  • [Cites] Curr HIV/AIDS Rep. 2008 May;5(2):78-85 [18510893.001]
  • [Cites] J Am Acad Dermatol. 2006 Feb;54(2):189-206; quiz 207-10 [16443048.001]
  • [Cites] Clin Infect Dis. 2004 Mar 1;38(5):737-42 [14986260.001]
  • [Cites] Dermatology. 2009;218(2):114-8 [19005244.001]
  • [Cites] J Drugs Dermatol. 2008 May;7(5):483-5 [18505144.001]
  • [Cites] Sex Transm Dis. 2006 Apr;33(4):259-64 [16452834.001]
  • [Cites] Obstet Gynecol. 2006 May;107(5):1023-8 [16648406.001]
  • [Cites] AIDS. 2003 Jan 24;17(2):279-80 [12545098.001]
  • [Cites] Clin Infect Dis. 2002 Nov 1;35(9):1127-34 [12384848.001]
  • [Cites] Antivir Ther. 2004 Feb;9(1):13-22 [15040532.001]
  • [Cites] JAMA. 2000 Feb 23;283(8):1031-7 [10697063.001]
  • [Cites] AIDS. 1998 Mar 26;12(5):495-503 [9543448.001]
  • [Cites] Cancer. 1994 Sep 15;74(6):1762-7 [8082079.001]
  • [Cites] J Reprod Med. 2005 Nov;50(11):807-10 [16419625.001]
  • [Cites] Dis Markers. 2007;23(4):261-72 [17627061.001]
  • [Cites] Neth J Med. 2008 Mar;66(3):98-102 [18349464.001]
  • [Cites] J Virol. 2002 Aug;76(15):7832-42 [12097595.001]
  • [Cites] Cutis. 2007 Apr;79(4):307-11 [17500379.001]
  • [Cites] AIDS. 2005 Sep 2;19(13):1407-14 [16103772.001]
  • [Cites] Med Wieku Rozwoj. 2003 Oct-Dec;7(4 Pt 1):487-93 [15010559.001]
  • [Cites] J Am Acad Dermatol. 1999 Nov;41(5 Pt 1):661-77; quiz 678-80 [10534627.001]
  • [Cites] Hum Vaccin. 2007 Jul-Aug;3(4):109-15 [17611417.001]
  • [Cites] AIDS Patient Care STDS. 1998 Apr;12(4):251-4 [11361951.001]
  • [Cites] J Am Acad Dermatol. 2005 Oct;53(4):737-9 [16198810.001]
  • [Cites] Lancet. 2006 Apr 15;367(9518):1247-55 [16631880.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] Virology. 2004 Jun 20;324(1):17-27 [15183049.001]
  • [Cites] J Natl Cancer Inst. 1999 Feb 3;91(3):226-36 [10037100.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2007 Sep;21(8):1054-60 [17714124.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):320-6 [9525432.001]
  • [Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/140-6 [16950001.001]
  • [Cites] Br J Dermatol. 2007 May;156(5):871-4 [17263801.001]
  • [Cites] Lancet. 2002 Jan 12;359(9301):108-13 [11809252.001]
  • [Cites] Arch Dermatol. 1998 Jan;134(1):25-30 [9449906.001]
  • [Cites] Ann Oncol. 2002 Mar;13(3):475-9 [11996481.001]
  • [Cites] Vaccine. 2008 Aug 19;26 Suppl 10:K53-61 [18847557.001]
  • [Cites] Cancer Invest. 2001;19(3):266-72 [11338884.001]
  • [Cites] Clin Dermatol. 1997 May-Jun;15(3):439-47 [9255449.001]
  • [Cites] Lancet Infect Dis. 2006 Jan;6(1):21-31 [16377531.001]
  • [Cites] J Infect Dis. 2003 Jul 15;188(2):327-38 [12854090.001]
  • [Cites] Cancer Sci. 2007 Oct;98(10):1505-11 [17645777.001]
  • [Cites] J Invest Dermatol. 2008 Sep;128(9):2316-24 [18385760.001]
  • [Cites] Clin Exp Obstet Gynecol. 2005;32(2):138-40 [16108402.001]
  • [Cites] Br J Dermatol. 2000 Jun;142(6):1148-53 [10848738.001]
  • [Cites] J Am Acad Dermatol. 2003 Mar;48(3):385-93 [12637918.001]
  • [Cites] Eur J Cancer. 2001 Jul;37(10):1227-35 [11423255.001]
  • [Cites] J Natl Cancer Inst Monogr. 2003;(31):52-6 [12807946.001]
  • [Cites] Dermatol Clin. 2006 Apr;24(2):157-65, vi [16677964.001]
  • [Cites] J Am Podiatr Med Assoc. 1998 Sep;88(9):442-5 [9770936.001]
  • [Cites] AIDS Patient Care STDS. 2007 Feb;21(2):78-80 [17328656.001]
  • [Cites] Cancer Treat Res. 2007;133:185-213 [17672042.001]
  • [Cites] J Am Acad Dermatol. 1996 Jun;34(6):1080-2 [8647978.001]
  • [Cites] AIDS. 2006 Nov 28;20(18):2337-44 [17117020.001]
  • [Cites] New Microbiol. 2007 Oct;30(4):377-82 [18080672.001]
  • [Cites] Lancet. 2005 Sep 17-23;366(9490):991-8 [16168781.001]
  • [Cites] Br J Dermatol. 2007 Dec;157 Suppl 2:52-5 [18067633.001]
  • [Cites] Br J Dermatol. 2007 Oct;157(4):788-94 [17634082.001]
  • [Cites] J Infect Dis. 2001 Feb 1;183(3):383-91 [11133369.001]
  • [Cites] J Acquir Immune Defic Syndr. 2001 Dec 15;28(5):422-8 [11744829.001]
  • [Cites] Dis Markers. 2007;23(4):247-59 [17627060.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Jan 1;17(1):94-5 [9436767.001]
  • [Cites] Cutis. 2007 Apr;79(4 Suppl):5-10 [17508490.001]
  • (PMID = 19589298.001).
  • [ISSN] 1548-3576
  • [Journal-full-title] Current HIV/AIDS reports
  • [ISO-abbreviation] Curr HIV/AIDS Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Papillomavirus Vaccines
  • [Number-of-references] 69
  •  go-up   go-down


6. Bonnet F, Burty C, Lewden C, Costagliola D, May T, Bouteloup V, Rosenthal E, Jougla E, Cacoub P, Salmon D, Chêne G, Morlat P, Agence Nationale de Recherches sur le Sida et les Hépatites Virales EN19 Mortalité Study Group, Mortavic Study Group: Changes in cancer mortality among HIV-infected patients: the Mortalité 2005 Survey. Clin Infect Dis; 2009 Mar 1;48(5):633-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in cancer mortality among HIV-infected patients: the Mortalité 2005 Survey.
  • BACKGROUND: The goal of the current study was to describe the distribution and characteristics of malignancy related deaths among human immunodeficiency virus (HIV)-infected patients with use of data obtained from a national survey conducted in France in 2005 and to compare with results obtained from a similar survey conducted in 2000.
  • RESULTS: Among the 1042 deaths reported in 2005 (964 were reported in 2000), 344 were cancer related (34%), which represented a significant increase from 2000 (29% of deaths were cancer related) (P=.02); 134 of the cancer-related deaths were AIDS related and 210 were not AIDS related.
  • Among the cancer-related causes of death, the proportion of hepatitis-related cancers (6% in 2000 vs. 11% in 2005) and non-AIDS/hepatitis-related cancers (38% in 2000 vs 50% in 2005) significantly increased from 2000 to 2005 (P=.03 and P=.01, respectively), compared with the proportion of cancer that was AIDS related and adjusting for age and sex.
  • Among cases involving AIDS, the proportion of non-Hodgkin lymphoma-associated deaths did not change statistically significantly between 2000 and 2005 (11% and 10% of deaths, respectively).
  • CONCLUSIONS: In this study, an increasing proportion of lethal non-AIDS-related cancers was demonstrated from 2000 to 2005; meanwhile, the proportion of lethal AIDS-related cancers remained stable among HIV-infected patients.
  • Thus, cancer prophylaxis, early diagnosis, and improved management should be included in the routine long-term follow-up of HIV-infected patients.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Infect Dis. 2009 Aug 1;49(3):481-2 [19586399.001]
  • [CommentIn] Clin Infect Dis. 2009 Mar 1;48(5):640-1 [19202628.001]
  • (PMID = 19202627.001).
  • [ISSN] 1537-6591
  • [Journal-full-title] Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • [ISO-abbreviation] Clin. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Investigator] Chêne G; Costagliola D; Jougla E; May T; Morlat P; Salmon D; Cacoub P; Rosenthal E; Bonnet F; Burty C; Lewden C; François M; Boileau J; Zouari H; Tourteau F; Bursacchi P; Delfraissy JF; Semaille C; Redecker S; Imbert Y; Rispal P; Allegre T; Riou J; Marquant M; Undreiner P; Abino J; Barel P; Greziller; Gosse; Lagier A; Bastide D; Schmit J; Decaux N; Chennebault J; Fialaire P; Abgueguen P; Loison J; Gaillat J; Legrand E; Dor J; Quinsat D; Lerousseau L; Chavaillon; Toquet-Maillet E; Sutton L; Genet P; Salord J; Raison G; Dubois D; Lierman Y; Bervar J; Castan B; Malbec D; Delassus J; Bakir R; Lepeu G; Pichancourt G; Theodourou-Touchais A; De La Blanchardiere OA; Evon P; Aubry Y; Giffo B; Bonnal F; Labarrere S; Amanieu M; Valet D; Faller J; Eglinger P; Duchene F; Humbert P; Dupond J; Estavoyer J; Hoen B; Roche C; Chirouze C; Faucher J; Oziol E; Saad A; Cabrol M; Gateau P; Seiberras S; Vidal C; Mazari A; Bentata M; Honore P; Bouchaud O; Bessin C; Jeantils V; Tassi S; Fain O; Dupon M; Morlat P; Beylot J; Lacoste D; Bonarek M; Bernard N; Bonnet F; Ragnaud J; Longy-Boursier M; Mercie P; Series C; Portal B; Terrier F; Rouveix E; Olivier C; Vaillant J; Moulias S; Hanslik T; Granier P; Colucci T; Mornet M; Aaron L; Guimard Y; Agbodjan J; Julien J; Fabre M; Garre M; Gouerou; Savary O; Nousbaum J; Granier H; Brousse P; Verdon R; Feret P; Guivarch; Sire S; Simonet P; Tempesta S; Vialatte B; Prudhomme L; Djossou F; Bichat S; Nacher M; Couppie P; Dellinger; Picard J; Sabbagh; Rogeaux O; Penalba C; Aubert C; Alba C; Galanaud P; Delavalle A; Boue F; Defuentes G; Pik J; Laurichesse H; Beytout J; Cormerais L; Fantin B; Uludag A; Mantz J; Cohen J; Kohser F; Plaisance N; Blaison G; Martinot M; Minozzi C; Ferreira C; Zeng F; Domart Y; Merrien D; Zylberait D; Devidas A; Turpauld I; Chevojon P; Bardet M; Jacquemard P; Sobel A; Jung C; Dumont C; Chousterman M; Housset B; Bassinet L; Schortgen F; Loste P; Antoniotti O; Nehme E; Granet P; Brunello; Portier H; Grappin M; Buisson M; Duong M; Braconnier C; Waldner-Combernoux A; Laine J; Brousse A; Cardon G; Visticot F; Vella M; Bonnevie F; Vanrenterghem; Soupison T; Gruat N; Roche J; Sicot; Saraux J; Lepretre A; El Hajj L; Frossard; Brung M; Lefebvre; Beguinot I; Schuhmacher H; Hirsch J; Reumont G; Saad; Galan; Estebe; Cabie A; Abel S; Quist D; Counillon E; Armero R; Del Giudice P; Gamblin V; Bouchard I; De Truchis P; Berthe H; Leclercq P; Brambilla C; Gineste E; Sarrot-Reynauld F; Jenny; Class J; Raynaud-Simon A; Alvarez F; Perre P; Aubry O; Suaud I; Courbes I; Batejat B; Dupont A; Lagarde P; David-Ouaknine F; Le Moigne E; Caumont B; Robin M; Hoel J; Doll J; Colardelle P; Roussin-Bretagne S; Greder A; Belan; Bedos J; Bruneel F; Thibous F; Lemeunier; Delfraissy J; Goujard C; Rannou M; Wind P; Monange B; Lamblin C; Cochonat K; Balquet M; De Ribes DC; Force G; Ceccaldi J; Marcos J; Hammou Y; Codaccioni X; Weinbreck P; Genet C; Debette-Gratien M; Geffray L; Le Mercier Y; Follet; Duvert B; Lacroix; Arnaud A; Selles Y; Levasseur F; Touraine J; Jeanblanc F; Trepo C; Benmakhlouf N; Lebouche B; Peyramond D; Boibieux A; Chidiac C; Delorme C; Carbonnel E; Baty V; Kisterman J; Roubert X; Granier F; Tremolières F; Billy C; Perronne V; Testaud J; Gastaut J; Drogoul M; Fabre G; Moreau J; Vandergheynst E; Bourliere M; Ruiz J; Philibert P; Gamby T; Petit N; Simon F; Fontaneau; Meissonnier P; Bayada J; Christian B; Armand A; Galzin M; Dumas D; De Witte S; Jobard J; Poncet A; Caillet B; Reynes J; De Boever CM; Siffert M; Bourgeois A; Villadoro A; Tramoni C; Faucherre V; Larrey D; Jonquet O; Landreau; Andre M; Winter C; Roge C; Beck-Wirth G; Drenou B; Benomar M; Ruel M; Chemlal K; Raffi F; Morineau-Le Houssine P; Le Bavec CG; Lemesre F; Masson B; Loison F; Razafimahery M; De Lacour JL; Dellamonica P; Mondain-Miton V; Cua E; Oran N; Valerio L; Rosenthal E; Fuzibet J; Tran A; Brocker P; Barrelier P; Vincent D; Mauboussin J; Barbuat C; Rouanet I; Jourdan N; Sotto A; Del Bucchia F; Jourdan J; Lapine M; Capdevielle P; Lacassin-Beller F; Droetto F; Diab G; Grihon F; Arsac P; Hocqueloux L; Levasseur M; Fourdilis M; Jarno P; Derouineau J; Morel P; Timsit F; Compagnucci A; Oksenhendler E; Gerard L; Delgado J; Sereni D; Lascoux-Combe C; Viard J; Dupont B; Maignan A; Bergmann J; Sellier P; Magnier J; Pialoux G; Godard V; Goetschel A; Lebrette M; Weiss L; Tisne-Dessus D; Leport C; Ecobichon J; Colasante U; Guillevin L; Salmon-Ceron D; Pietri M; Brunet A; Silbermann B; Blanche P; Schoen H; Valantin M; Hausfater P; Martinez V; Herson S; Simon A; Brancon C; Girard P; Begle A; Raguin G; Lupin C; Molina J; Ponscarme D; Garrait V; Cabotin P; Janier M; Spindler E; Yeni P; Gerbe J; Cabane J; Ziza J; Aerts J; Carlet J; Gilquin J; Auperin I; Misset B; Crof A; Piette J; Cacoub P; Turpin G; Varet B; Dupin N; Le Jeunne C; Aslangul E; Pol S; Poynard T; Lebray P; Carbonell N; Benlian P; Goujon M; Dhainaut J; Charpentier J; Andrieu J; Brunel M; Landgraf N; Bary M; Pouyanne; Meraud J; Riviere C; Aumaître H; Saada M; Cros H; Pellegrin J; Adjeoda R; Durieu I; Rousset H; Vital-Durand D; Lamaury I; Sow M; Hillion D; Masson H; Becq-Giraudon B; Le Moal G; Silvain C; Danne O; Blum L; Larzul J; Perfezou P; Rouger C; Novella J; Michelet C; Tattevin P; Arvieux C; Souala F; Delmont-Hanry M; Guyader D; Gandemer V; Camus C; Taverson; Lutz M; Climas M; Wemeau J; Gueit I; Suel P; Caron F; Mechali D; Khuong-Josses M; Etienne Y; Lucht F; Fresard A; Ronat V; Vergnon; Garcier; Deluca J; Randrianjohany A; Monnot H; Poubeau P; Andre H; Beuscart C; Aubry M; Hurbin E; Debord T; Rapp C; Bissuel F; Walter V; Ferret J; Bonnefoy M; Riche A; Marot J; Michau C; Bonnin E; Pasdeloup T; Chaby G; Grilliat E; Wurtz E; Loth F; Kitschke B; Line D; Gaud C; Sautron C; Cathebras P; Welker Y; Sandron D; Lang J; Fischer P; Pasquali J; Lalanne H; Chartier C; Berlin C; Andres E; Christmann D; Hansmann Y; Fraisse P; Bletry O; Zucman D; Majerholc C; Stern M; Couderc L; Petitou J; Truchetet F; Pouaha J; Romand P; Lafeuillade A; Lambry V; Bernard P; Adoue D; Duffaut M; Marchou B; Garipuy D; Cuzin L; Marchou B; Garipuy D; Cuzin L; Uzan M; Vinel J; Metivier S; Didier A; Rouquet R; Mouton Y; Yazdanpanah Y; Marysse F; Guery B; Faure K; Besnier J; Le Bret P; Nau P; Sigogneau H; Bressieux J; Libbrecht E; Rezzouk L; Collignon A; Ponceau B; Kyndt X; Vermersch-Langlin A; May T; Burty C; Lederlin P; Poinsignon Y; Creusat C; Richard C; Merle C; Essayan A; Vittecoq D; Bolliot C; Quignard; Patey O; Dellion S; Chossat I
  •  go-up   go-down


7. Mortimer RB, Libke R, Eghbalieh B, Bilello JF: Immune reconstitution inflammatory syndrome presenting as superior vena cava syndrome secondary to Coccidioides lymphadenopathy in an HIV-infected patient. J Int Assoc Physicians AIDS Care (Chic); 2008 Nov-Dec;7(6):283-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 39-year-old man living with AIDS presented with a swollen face.
  • Biopsy confirmed coccidioidomycosis with no evidence of malignancy.
  • [MeSH-minor] AIDS-Related Opportunistic Infections / complications. Adult. Coccidioides. HIV Infections / complications. HIV-1. Humans. Male


8. Isshiki I, Okamoto S, Kakimoto T, Chen CK, Mori T, Yokoyama K, Hattori Y, Ikeda Y: Recurrence of autoimmune disease after autologous peripheral blood stem cell transplantation for multiple myeloma. Int J Hematol; 2006 Nov;84(4):354-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There have been a number of reports on the improvement of concomitant autoimmune disease (AID) after autologous hematopoietic stem cell transplantation (SCT) performed for hematologic malignancy.
  • However, in some cases of hematologic malignancy with AID, exacerbation of AID after autologous SCT has been reported.
  • The RA and BP were in durable remission before SCT, and no Sjögren syndrome-related disease activity was clinically documented at the time of SCT.
  • No progression of the myeloma was observed when the AIDs recurred.

  • Genetic Alliance. consumer health - Multiple myeloma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arthritis Rheum. 1997 Sep;40(9):1712-5 [9324027.001]
  • [Cites] Rheumatology (Oxford). 1999 Aug;38(8):762-3 [10501429.001]
  • [Cites] Bone Marrow Transplant. 2000 Sep;26(6):673-5 [11035374.001]
  • [Cites] Bone Marrow Transplant. 1997 Jun;19(12):1247-50 [9208120.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3052-7 [15265788.001]
  • [Cites] Arthritis Rheum. 1995 Mar;38(3):301-5 [7880182.001]
  • [Cites] J Rheumatol Suppl. 1997 May;48:79-84 [9150124.001]
  • [Cites] J Exp Med. 1964 Oct 1;120:547-60 [14212118.001]
  • [Cites] Ann Rheum Dis. 2001 Feb;60(2):174-6 [11203719.001]
  • [Cites] J Rheumatol Suppl. 1997 May;48:1-4 [9150110.001]
  • [Cites] Bone Marrow Transplant. 2005 May;35(9):869-79 [15765114.001]
  • [Cites] Blood. 1996 Nov 1;88(9):3621-5 [8896432.001]
  • [Cites] J Immunol. 1996 Jan 15;156(2):794-803 [8543835.001]
  • [Cites] Rheumatology (Oxford). 1999 Aug;38(8):767-72 [10501431.001]
  • [Cites] N Engl J Med. 2003 May 8;348(19):1875-83 [12736280.001]
  • [Cites] Bone Marrow Transplant. 2002 Oct;30(8):527-9 [12379893.001]
  • [Cites] J Rheumatol Suppl. 1997 May;48:100-2 [9150129.001]
  • [Cites] Bone Marrow Transplant. 2000 Oct;26(8):925-7 [11081398.001]
  • [Cites] J Rheumatol Suppl. 1997 May;48:72-8 [9150123.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1602-10 [12176878.001]
  • [Cites] Arthritis Rheum. 2002 Sep;46(9):2301-9 [12355477.001]
  • [Cites] Bone Marrow Transplant. 1998 Oct;22(7):729-31 [9818705.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2364-72 [12763935.001]
  • [Cites] Bone Marrow Transplant. 1993 Mar;11(3):183-7 [8467280.001]
  • [Cites] J Neuroimmunol. 1992 Aug;39(3):201-10 [1644896.001]
  • [Cites] Haematologica. 2000 Aug;85(8):832-8 [10942930.001]
  • [Cites] Bone Marrow Transplant. 1997 Apr;19(7):745-7 [9156254.001]
  • [Cites] N Engl J Med. 1996 Jul 11;335(2):91-7 [8649495.001]
  • [Cites] Bone Marrow Transplant. 1997 Apr;19(7):643-5 [9156239.001]
  • [Cites] Rheumatology (Oxford). 1999 Aug;38(8):757-61 [10501428.001]
  • [Cites] Bone Marrow Transplant. 1998 Jul;22(2):211-3 [9707034.001]
  • (PMID = 17118763.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Steroids; Q41OR9510P / Melphalan
  •  go-up   go-down


9. Noy A: Update in HIV lymphoma. Curr Opin Oncol; 2006 Sep;18(5):449-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE OF REVIEW: Despite the control of HIV infection in industrialized nations, individuals infected with HIV remain at increased risk of malignancies.
  • Lymphoma is the most common HIV-associated malignancy in these countries.
  • RECENT FINDINGS: Investigators continue to demonstrate that HIV-associated non-Hodgkin's lymphoma remains a significant problem, even in the era of highly active antiretroviral therapy.
  • The latter improves complete response rates, but is associated with an increased incidence of infections.
  • Biological insights have been gained into the spectrum of HIV-associated non-Hodgkin's lymphoma and Hodgkin's disease, and include further work on virological co-infections.
  • [MeSH-major] Anti-Retroviral Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, AIDS-Related / drug therapy

  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16894292.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents
  • [Number-of-references] 45
  •  go-up   go-down


10. Crum NF, Riffenburgh RH, Wegner S, Agan BK, Tasker SA, Spooner KM, Armstrong AW, Fraser S, Wallace MR, Triservice AIDS Clinical Consortium: Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr; 2006 Feb 1;41(2):194-200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Comparisons of death-related variables during the 3 eras were performed.
  • The proportion of deaths attributable to infection decreased, but infection remained the leading cause of death in our cohort, followed by cancer.
  • Of those who died, there was an increasing proportion of non-HIV-related deaths (32% vs. 9%; P < 0.01), including cardiac disease (22% vs. 8%; P < 0.01) and trauma (8% vs. 2%; P = 0.01) in the post-HAART versus pre-HAART era.
  • A shift in the causes of death toward non-HIV-related causes suggests that a more comprehensive health care approach may be needed for optimal life expectancy; this may include enhanced screening for malignancy and heart disease as well as preventive measures for liver disease and accidents.


11. Riggs RM, McCarthy J: Vulvar Kaposi's sarcoma in a woman with AIDS: a case report. J Reprod Med; 2005 Sep;50(9):730-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vulvar Kaposi's sarcoma in a woman with AIDS: a case report.
  • BACKGROUND: Kaposi's sarcoma is the most common malignancy among HIV patients.
  • CASE: A 38-year-old, multiparous woman and AIDS patient presented with left vulvar edema and pain.
  • [MeSH-major] AIDS-Related Opportunistic Infections / etiology. Acquired Immunodeficiency Syndrome / complications. Sarcoma, Kaposi / etiology. Vulvar Neoplasms / etiology


12. Pancharoen C, Nuchprayoon I, Thisyakorn U, Chokephaibulkit K, Veerakul G, Punpanich W, Kanjanapongkul S, Mekmullica J, Wongsawat J, Bowonkiratikachorn P, Hongsiriwon S, Thanarattanakorn P, Kosalaraksa P, Wiangnon S, Saerejittima A, Kochavate S: Hospital-based epidemiologic survey of malignancies in children infected with human immunodeficiency virus in Thailand. Pediatr Infect Dis J; 2005 Oct;24(10):923-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hospital-based epidemiologic survey of malignancies in children infected with human immunodeficiency virus in Thailand.
  • To determine the incidence and spectrum of malignancies in human immunodeficiency virus-infected children, we surveyed 48 hospitals in Thailand between 1996 and 2000.
  • There were 23 children (14 boys and 9 girls; average age at diagnosis of malignancy, 4.2 years), and the incidence rate was 0.6 per 1000 person-years.
  • The most common malignancy was lymphoma (87.0%).
  • [MeSH-major] AIDS-Related Opportunistic Infections / epidemiology. HIV Infections / complications. HIV Infections / epidemiology. Hospitals. Lymphoma, AIDS-Related / epidemiology. Neoplasms / epidemiology


13. Northup JK, Gadre SA, Ge Y, Lockhart LH, Velagaleti GV: Do cytogenetic abnormalities precede morphologic abnormalities in a developing malignant condition? Eur J Haematol; 2007 Feb;78(2):152-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Do cytogenetic abnormalities precede morphologic abnormalities in a developing malignant condition?
  • Here, we highlight two cases in which the cytogenetic studies challenge the common practice of using hematologic and morphologic changes as key factors in malignant disease management.
  • Cytogenetic studies of lymph node showed multiple clonal abnormalities, most notably a der(18) from a t(14;18) which is associated with high-grade NHL.
  • Hematologic studies of ascitic fluid classified the patient as having pleural effusion lymphoma whereas bone marrow analysis showed no malignancy.
  • Bone marrow cytogenetic studies showed multiple clonal abnormalities including a t(8;14), which is commonly associated with Burkitt's lymphoma (BL).
  • These studies clearly demonstrate that genetic changes often precede morphologic changes in a developing malignant condition.
  • Therefore, the critical information needed for care of patients with malignant disorders may be incomplete or inaccurate if cytogenetic evaluation is overlooked.
  • [MeSH-major] Burkitt Lymphoma / genetics. Lymphoma, AIDS-Related / genetics. Lymphoma, Follicular / genetics. Lymphoma, Non-Hodgkin / genetics. Translocation, Genetic
  • [MeSH-minor] Adult. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow / pathology. Chromosomes, Human, Pair 12 / ultrastructure. Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, Pair 14 / ultrastructure. Chromosomes, Human, Pair 18 / genetics. Chromosomes, Human, Pair 18 / ultrastructure. Chromosomes, Human, Pair 8 / genetics. Chromosomes, Human, Pair 8 / ultrastructure. Chromosomes, Human, X. Clone Cells / pathology. Cyclophosphamide / administration & dosage. Disease Progression. Doxorubicin / administration & dosage. Drug Resistance, Neoplasm. Female. Genes, myc. Humans. Karyotyping. Lymph Nodes / pathology. Male. Mutagenesis, Insertional. Pleural Effusion, Malignant / drug therapy. Pleural Effusion, Malignant / genetics. Pleural Effusion, Malignant / pathology. Prednisone / administration & dosage. Rituximab. Trisomy. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives. Vincristine / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17313561.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


14. Krishnan A, Forman SJ: Hematopoietic stem cell transplantation for AIDS-related malignancies. Curr Opin Oncol; 2010 Sep;22(5):456-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematopoietic stem cell transplantation for AIDS-related malignancies.
  • PURPOSE OF REVIEW: AIDS-related malignancies are an ongoing cause of mortality in individuals with HIV infection.
  • In the HIV-negative setting, high-dose chemotherapy or stem cell transplantation is an option for patients with hematologic malignancies.
  • RECENT FINDINGS: Early autologous stem cell transplantation has studies had high relapse rates but they demonstrated that mobilization and engraftment of autologous stem cells were possible in AIDS patients.
  • Recently, in less advanced AIDS lymphoma, autologous stem cell transplantation has resulted in low transplant-related mortality and durable remissions.
  • In addition, case-control studies of HIV-positive versus HIV-negative lymphoma patients undergoing autologous stem cell transplantation have shown similar transplant-related mortality and overall survival.
  • SUMMARY: The potential future applications of autologous and allogeneic stem cell transplantation are the cure of the malignancy as well as the underlying HIV infection by either transplantation of naturally resistant or genetically modified stem cells.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, AIDS-Related / therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Transplantation.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2002 Jul 25;347(4):284-7 [12140307.001]
  • [Cites] Blood. 2009 Aug 13;114(7):1306-13 [19451551.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):317-24 [15241829.001]
  • [Cites] Blood. 1989 Apr;73(5):1340-50 [2649174.001]
  • [Cites] Cancer. 1991 Dec 1;68(11):2466-72 [1933784.001]
  • [Cites] Bone Marrow Transplant. 1996 Dec;18(6):1195-7 [8971396.001]
  • [Cites] N Engl J Med. 1998 Mar 26;338(13):853-60 [9516219.001]
  • [Cites] Cancer Res. 1999 Aug 1;59(15):3561-4 [10446961.001]
  • [Cites] Blood. 2005 Jan 15;105(2):874-8 [15388574.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4123-8 [16896005.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jan;14(1):59-66 [18158962.001]
  • [Cites] Blood. 2008 Oct 15;112(8):3484-7 [18698002.001]
  • [Cites] N Engl J Med. 2009 Feb 12;360(7):692-8 [19213682.001]
  • [Cites] J Clin Oncol. 2009 May 1;27(13):2192-8 [19332732.001]
  • [Cites] Blood. 2009 Jun 4;113(23):6011-4 [19307667.001]
  • [Cites] AIDS. 2003 Jul 4;17(10):1521-9 [12824790.001]
  • (PMID = 20639760.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA030206; United States / NCI NIH HHS / CA / P30 CA033572; United States / NCI NIH HHS / CA / P30 CA033572; United States / NCI NIH HHS / CA / P50 CA107399
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS427480; NLM/ PMC3537514
  •  go-up   go-down


15. Venkatanarasimha N: HIV, HAART, and IRIS: tuberculosis versus malignancy. AJR Am J Roentgenol; 2010 Nov;195(5):W376
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV, HAART, and IRIS: tuberculosis versus malignancy.
  • [MeSH-major] AIDS-Related Opportunistic Infections / diagnosis. AIDS-Related Opportunistic Infections / drug therapy. Antiretroviral Therapy, Highly Active. Tuberculosis / diagnosis. Tuberculosis / drug therapy


16. Maertens J, Egerer G, Shin WS, Reichert D, Stek M, Chandwani S, Shivaprakash M, Viscoli C, Study Team CAN-DOIA: Caspofungin use in daily clinical practice for treatment of invasive aspergillosis: results of a prospective observational registry. BMC Infect Dis; 2010;10:182
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignancy (76.7%), neutropenia (64.1%), allogeneic hematopoietic stem cell transplantation (HSCT, 22.3%), solid organ transplantation (8.7%), autologous HSCT (4.9%), and HIV/AIDS (2.9%) were the most common underlying conditions.
  • Favorable response rates in clinically relevant subgroups were: malignancy, 51.9% (41/79); allogeneic HSCT, 56.5% (13/23); and neutropenia at time of hospitalization, 53.0% (35/66).
  • Serious adverse events related to caspofungin were reported in 4 cases (3.9%); 3 patients (2.9%) discontinued treatment due to an adverse event related to caspofungin.
  • CONCLUSIONS: Caspofungin was both effective and well tolerated among high-risk patient groups such as those with neutropenia and active malignancies.

  • Genetic Alliance. consumer health - Aspergillosis.
  • MedlinePlus Health Information. consumer health - Aspergillosis.
  • HIV InSite. treatment guidelines - Aspergillosis and HIV .
  • Hazardous Substances Data Bank. CASPOFUNGIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Infect Dis. 2001 Feb 1;32(3):358-66 [11170942.001]
  • [Cites] J Postgrad Med. 2001 Jan-Mar;47(1):45-50 [11590294.001]
  • [Cites] Clin Infect Dis. 2002 Jan 1;34(1):7-14 [11731939.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2002 Mar;21(3):161-72 [11957017.001]
  • [Cites] N Engl J Med. 2002 Aug 8;347(6):408-15 [12167683.001]
  • [Cites] Clin Infect Dis. 2008 Feb 1;46(3):327-60 [18177225.001]
  • [Cites] Clin Infect Dis. 2004 Dec 1;39(11):1563-71 [15578352.001]
  • [Cites] Bone Marrow Transplant. 2005 Nov;36(10):873-7 [16113663.001]
  • [Cites] J Antimicrob Chemother. 2006 Jan;57(1):127-34 [16308418.001]
  • [Cites] Cancer. 2006 Dec 15;107(12):2888-97 [17103444.001]
  • [Cites] Clin Infect Dis. 2007 May 15;44(10):1289-97 [17443465.001]
  • [Cites] Drug Resist Updat. 2003 Aug;6(4):197-218 [12962685.001]
  • (PMID = 20569436.001).
  • [ISSN] 1471-2334
  • [Journal-full-title] BMC infectious diseases
  • [ISO-abbreviation] BMC Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Echinocandins; F0XDI6ZL63 / caspofungin
  • [Other-IDs] NLM/ PMC2914768
  •  go-up   go-down


17. Blanes M, Belinchón I, Merino E, Portilla J, Sánchez-Payá J, Betlloch I: [Current prevalence and characteristics of dermatoses associated with human immunodeficiency virus infection]. Actas Dermosifiliogr; 2010 Oct;101(8):702-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Current prevalence and characteristics of dermatoses associated with human immunodeficiency virus infection].
  • The frequency of opportunistic infections and AIDS-related cancers has fallen, though new health problems have developed.

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20965013.001).
  • [ISSN] 1578-2190
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  •  go-up   go-down


18. Data Collection on Adverse Events of Anti-HIV drugs (D:A:D) Study Group, Smith C, Sabin CA, Lundgren JD, Thiebaut R, Weber R, Law M, Monforte Ad, Kirk O, Friis-Moller N, Phillips A, Reiss P, El Sadr W, Pradier C, Worm SW: Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS; 2010 Jun 19;24(10):1537-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study.
  • OBJECTIVE: To investigate any emerging trends in causes of death amongst HIV-positive individuals in the current cART era, and to investigate the factors associated with each specific cause of death.
  • Primary causes of death were: AIDS (n = 743; rate/1000 PY = 4.12), liver-related (341; 1.89), CVD-related (289; 1.60), non-AIDS malignancy (286; 1.59).
  • Smoking was associated with CVD and non-AIDS cancers, HBV and HCV co-infection with liver-related deaths, and hypertension with liver-related and CVD deaths.
  • Diabetes was a risk factor for all specific causes of death except non-AIDS cancers, and higher current HIV RNA for AIDS-related deaths.
  • Lower CD4 cell counts were associated with a higher risk of death from all specific causes of death.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] AIDS. 2011 Mar 27;25(6):883. multiple author names added
  • (PMID = 20453631.001).
  • [ISSN] 1473-5571
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0701639; United States / NIAID NIH HHS / AI / 5U01AI042170-10; United States / NIAID NIH HHS / AI / 5U01AI046362-03; United States / NIAID NIH HHS / AI / U01-AI069907
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Investigator] Worm SW; Friis-Møller N; Sabin CA; Sjøl A; Lundgren JD; Salbøl-Brandt R; Rickenbach M; Pezzotti P; Krum E; Gras L; Balestre E; Sundström A; Delforge M; Fontas E; Torres F; Petoumenos K; Kjaer J; Collins S; Storpher S; Pearce G; Rode R; Weller I
  •  go-up   go-down


19. Desmet S, Van Wijngaerden E, Maertens J, Verhaegen J, Verbeken E, De Munter P, Meersseman W, Van Meensel B, Van Eldere J, Lagrou K: Serum (1-3)-beta-D-glucan as a tool for diagnosis of Pneumocystis jirovecii pneumonia in patients with human immunodeficiency virus infection or hematological malignancy. J Clin Microbiol; 2009 Dec;47(12):3871-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum (1-3)-beta-D-glucan as a tool for diagnosis of Pneumocystis jirovecii pneumonia in patients with human immunodeficiency virus infection or hematological malignancy.
  • (1-3)-Beta-D-Glucan (BG) reactivity was tested in serum samples from 28 patients with human immunodeficiency virus infection or a hematological malignancy and Pneumocystis jirovecii pneumonia (PCP) and 28 control patients.
  • [MeSH-major] AIDS-Related Opportunistic Infections / diagnosis. HIV Infections / complications. Hematologic Neoplasms / complications. Pneumocystis jirovecii. Pneumonia, Pneumocystis / diagnosis. beta-Glucans


20. Bannur HB, Malur PR, Dhorigol VM: Tubercular orchitis in a patient with AIDS: report of a case with fine needle aspiration diagnosis. Acta Cytol; 2007 May-Jun;51(3):459-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tubercular orchitis in a patient with AIDS: report of a case with fine needle aspiration diagnosis.
  • BACKGROUND: Although tuberculosis is one of the most common opportunistic infections in AIDS, the testis is rarely involved.
  • Clinically, tubercular orchitis mimics malignancy.
  • Clinically, malignancy was suspected.
  • CONCLUSION: FNA is a useful modality in differentiating tuberculosis from malignancy.
  • To the best of our knowledge, this is the third reported case of AIDS presenting as testicular tuberculosis.
  • [MeSH-major] AIDS-Related Opportunistic Infections / pathology. Acquired Immunodeficiency Syndrome / complications. HIV-1 / isolation & purification. Orchitis / pathology. Tuberculosis, Male Genital / pathology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17536555.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HIV Antibodies
  •  go-up   go-down


21. Spano JP, Costagliola D, Katlama C, Mounier N, Oksenhendler E, Khayat D: AIDS-related malignancies: state of the art and therapeutic challenges. J Clin Oncol; 2008 Oct 10;26(29):4834-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related malignancies: state of the art and therapeutic challenges.
  • Despite the impact of combination antiretroviral therapy (cART) on HIV-related mortality, malignancy remains an important cause of death in the current era.
  • Although the advent of cART has resulted in reductions in the incidence of Kaposi's sarcoma and non-Hodgkin's lymphoma, non-AIDS-defining malignancies present an increased risk for HIV-infected patients, characterized by some common clinical features, generally with a more aggressive behavior and a more advanced disease at diagnosis, which is responsible for poorer patient outcomes.
  • Specific therapeutic recommendations are lacking for these new nonopportunistic malignancies, such as Hodgkin's lymphoma, anal cancer, lung cancer, hepatocarcinoma, and many others.
  • Special considerations of these AIDS-related and non-AIDS-related malignancies and their clinical and therapeutic aspects constitute the subject of this review.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18591544.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 99
  •  go-up   go-down


22. Cáceres W, Cruz-Amy M, Díaz-Meléndez V: AIDS-related malignancies: revisited. P R Health Sci J; 2010 Mar;29(1):70-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related malignancies: revisited.
  • Since the first reports between the association of Human Immunodeficiency Virus (HIV) infection and neoplasia, there has been a dramatic change in the incidence and epidemiology of AIDS-related malignancies.
  • Kaposi sarcoma (KS), non-Hodgkin's lymphomas (NHL), and cervical cancer are classified by the Centers for Disease Control and Prevention (CDC) as AIDS-defining malignancies.
  • However, since the availability of highly active combination antiretroviral therapy (cART), especially protease inhibitors, there has been a steady increase in non- AIDS defining malignancies, such as Hodgkin's lymphoma (HL), lung cancer, hepatocellular cancer, anal cancer and others and a decline in AIDS-defining neoplasias.
  • Although the emergence of non-AIDS defining cancers could be a result of longer life expectancy and due to a better control of HIV, toxic habits and co-infection with other viruses such as hepatitis B, hepatitis C and human papilloma virus (HPV) could play an important role.
  • The interactions of cART and incomplete immune reconstitution could be other factors explaining the increase in non-AIDS defining cancers.
  • These emerging non-AIDS defining malignancies present a new challenge in the care of patients with HIV infection, and require optimal treatment protocols that take into consideration the interaction between cART and systemic chemotherapy.
  • We review the current status of AIDS-related malignancies, its pathophysiology, epidemiology and management with emphasis in the changing patterns of presentation.
  • [MeSH-minor] Humans. Lymphoma, AIDS-Related / epidemiology


23. Satyanarayana S, Nema S, Kalghatgi AT, Mehta SR, Rai R, Duggal R, Bhardwaj JR: Disseminated Strongyloides stercoralis in AIDS: a report from India. Indian J Pathol Microbiol; 2005 Oct;48(4):472-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disseminated Strongyloides stercoralis in AIDS: a report from India.
  • We report a fatal case of disseminated strongyloidiasis masquerading clinically as stage IV caecal malignancy diagnosed at post mortem by needle necropsy.
  • Enteric organisms like Group D streptococci and candida sp were also associated.
  • We believe that this is the first report of widespread dissemination of S. stercoralis in AIDS from India.
  • [MeSH-major] AIDS-Related Opportunistic Infections / diagnosis. Strongyloides stercoralis. Strongyloidiasis / complications. Strongyloidiasis / diagnosis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16366097.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


24. Gutiérrez F, Masiá M, Padilla S, Ramos JM, Bernal E, Morales P, Pozo F, Andrada E, Martin-Hidalgo A: Occult lymphadenopathic Kaposi's sarcoma associated with severe pulmonary hypertension: A clinical hint about the potential role of HHV-8 in HIV-related pulmonary hypertension? J Clin Virol; 2006 Oct;37(2):79-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occult lymphadenopathic Kaposi's sarcoma associated with severe pulmonary hypertension: A clinical hint about the potential role of HHV-8 in HIV-related pulmonary hypertension?
  • PH shares several histopathologic features with Kaposi's sarcoma (KS), the most common malignancy in AIDS patients, and molecular evidence of the vasculotropic Kaposi's sarcoma-associated herpesvirus or human herpesvirus 8 (HHV-8) has been found in the lung tissue of patients with the disease.
  • This is the first ever-reported case of PH associated with KS.
  • Although the co-occurrence of both diseases in this patient could have been just a coincidence, the observation may also indicate that a relationship between HHV-8 infection and HIV-associated PH exists.


25. Ramírez-Olivencia G, Valencia-Ortega ME, Martin-Carbonero L, Moreno-Celda V, González-Lahoz J: [Malignancies in HIV infected patients: study of 139 cases]. Med Clin (Barc); 2009 Nov 21;133(19):729-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignancies in HIV infected patients: study of 139 cases].
  • The purpose of this study was to describe the types of tumor, clinical features and prognosis of HIV infected patients with malignant diseases.
  • Information was collected on age, sex, risk factors for HIV, HBV/HCV coinfection, malignancies, diagnosis of AIDS, viral load and CD4 cell counts at diagnosis, antiretroviral therapy and mortality.
  • A total of 139 HIV-infected patients were identified who had at least one malignancy.
  • RESULTS: Types of malignancy were Kaposi's Sarcoma (n=43, 30.9%); non-Hodgkin lymphoma (n=42, 30.2%); gynecologic malignancy (n=16, 11.5%); Hodgkin's disease (n=15, 10.8%); hepatocellular carcinoma (n=7, 5%) and others (n=16, 11.5%).
  • There were 77 (55.4%) patients on HAART when cancer was diagnosed.
  • CONCLUSIONS: Increased survival of HIV-infected patients receiving HAART makes it possible the development of secondary tumors and AIDS- unrelated malignancies, sometimes related to another virus.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19880148.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


26. Shackelford J, Pagano JS: Role of the ubiquitin system and tumor viruses in AIDS-related cancer. BMC Biochem; 2007;8 Suppl 1:S8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of the ubiquitin system and tumor viruses in AIDS-related cancer.
  • Tumor viruses are linked to approximately 20% of human malignancies worldwide.
  • This review focuses on examples of human oncogenic viruses that manipulate the ubiquitin system in a subset of viral malignancies; those associated with AIDS.
  • The viruses include Kaposi's sarcoma herpesvirus, Epstein-Barr virus and human papilloma virus, which are causally linked to Kaposi's sarcoma, certain B-cell lymphomas and cervical cancer, respectively.
  • We discuss the molecular mechanisms by which these viruses subvert the ubiquitin system and potential viral targets for anti-cancer therapy from the perspective of this system.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr HIV Res. 2004 Oct;2(4):343-9 [15544455.001]
  • [Cites] Cell Cycle. 2004 Nov;3(11):1345-7 [15492505.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13057-62 [11087859.001]
  • [Cites] Acta Virol. 2000 Jun-Aug;44(3):211-26 [11155368.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1218-23 [11158620.001]
  • [Cites] Eur J Cancer. 2001 Jul;37(10):1227-35 [11423255.001]
  • [Cites] J Virol. 2001 Aug;75(16):7583-91 [11462030.001]
  • [Cites] Oncogene. 2001 Aug 2;20(34):4740-9 [11498796.001]
  • [Cites] Chem Biol. 2001 Aug;8(8):739-58 [11514224.001]
  • [Cites] Am J Clin Pathol. 2001 Nov;116(5):637-46 [11710679.001]
  • [Cites] J Cell Biol. 2001 Dec 24;155(7):1265-73 [11756476.001]
  • [Cites] J Biol Chem. 2002 Feb 22;277(8):6124-30 [11751860.001]
  • [Cites] Nat Med. 2002 Apr;8(4):338-40 [11927937.001]
  • [Cites] EMBO J. 2002 May 15;21(10):2418-29 [12006494.001]
  • [Cites] Oncology (Williston Park). 2002 May;16(5):657-65; discussion 665, 668-70 [12108891.001]
  • [Cites] Oral Dis. 2002;8 Suppl 2:161-8 [12164651.001]
  • [Cites] Curr Top Microbiol Immunol. 2002;269:23-36 [12224511.001]
  • [Cites] Cancer Lett. 2002 Dec 15;188(1-2):15-24 [12406543.001]
  • [Cites] Virus Res. 2002 Nov;89(2):213-28 [12445661.001]
  • [Cites] Semin Cancer Biol. 2002 Dec;12(6):431-41 [12450729.001]
  • [Cites] Semin Cancer Biol. 2003 Feb;13(1):59-67 [12507557.001]
  • [Cites] Semin Cancer Biol. 2003 Feb;13(1):69-76 [12507558.001]
  • [Cites] J Pathol. 2003 Feb;199(2):140-5 [12533825.001]
  • [Cites] Carcinogenesis. 2003 Feb;24(2):159-69 [12584163.001]
  • [Cites] Hum Mutat. 2003 Mar;21(3):307-12 [12619117.001]
  • [Cites] Microbiol Mol Biol Rev. 2003 Jun;67(2):175-212, table of contents [12794189.001]
  • [Cites] Med Sci (Paris). 2003 Jan;19(1):100-6 [12836198.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):697-702, v-vi [12852651.001]
  • [Cites] Virology. 2004 Jun 20;324(1):17-27 [15183049.001]
  • [Cites] Isr Med Assoc J. 2004 Jul;6(7):420-4 [15274534.001]
  • [Cites] Trends Immunol. 2004 Aug;25(8):422-6 [15275641.001]
  • [Cites] Cancer Chemother Biol Response Modif. 2003;21:717-46 [15338771.001]
  • [Cites] Semin Cancer Biol. 2004 Dec;14(6):453-71 [15489139.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):757-68 [15510157.001]
  • [Cites] Science. 1989 Feb 17;243(4893):934-7 [2537532.001]
  • [Cites] EMBO J. 1989 Dec 20;8(13):4099-105 [2556261.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):630-9 [15659509.001]
  • [Cites] Annu Rev Med. 2005;56:29-44 [15660500.001]
  • [Cites] Immunity. 2005 Jan;22(1):59-70 [15664159.001]
  • [Cites] Viral Immunol. 2004;17(4):473-80 [15671745.001]
  • [Cites] Cleve Clin J Med. 2005 Jan;72(1):73-8 [15691060.001]
  • [Cites] Crit Rev Oncol Hematol. 2005 Mar;53(3):253-65 [15718150.001]
  • [Cites] Curr Med Chem. 2005;12(3):357-74 [15723624.001]
  • [Cites] Expert Opin Emerg Drugs. 2005 Feb;10(1):5-19 [15757400.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2005;45:465-76 [15822185.001]
  • [Cites] J Virol. 2005 May;79(9):5705-12 [15827185.001]
  • [Cites] Am J Clin Pathol. 2005 Feb;123(2):222-8 [15842046.001]
  • [Cites] Anticancer Drugs. 2005 Jun;16(5):475-81 [15846112.001]
  • [Cites] Cell Cycle. 2005 Feb;4(2):290-6 [15655370.001]
  • [Cites] Mem Inst Oswaldo Cruz. 2005 Feb;100(1):1-12 [15867955.001]
  • [Cites] AIDS Rev. 2005 Jan-Mar;7(1):56-61 [15875661.001]
  • [Cites] Oncologist. 2005 Jun-Jul;10(6):412-26 [15967835.001]
  • [Cites] Science. 2005 Jul 1;309(5731):127-30 [15994556.001]
  • [Cites] J Antimicrob Chemother. 2005 Aug;56(2):277-81 [16006448.001]
  • [Cites] EMBO J. 2006 Apr 19;25(8):1635-45 [16601694.001]
  • [Cites] Adv Dent Res. 2006;19(1):99-105 [16672559.001]
  • [Cites] Lancet. 2006 May 6;367(9521):1495-502 [16679162.001]
  • [Cites] Curr Mol Med. 2006 May;6(3):291-308 [16712476.001]
  • [Cites] Front Biosci. 2006;11:2672-713 [16720343.001]
  • [Cites] Cancer Treat Rev. 2006 Oct;32(6):445-55 [16860939.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9870-7 [17047048.001]
  • [Cites] Mol Cell Biol. 2007 Apr;27(8):2910-8 [17296724.001]
  • [Cites] Adv Cancer Res. 2000;78:1-29 [10547667.001]
  • [Cites] Oncogene. 1999 Dec 13;18(53):7690-700 [10618709.001]
  • [Cites] Virology. 2000 Mar 1;268(1):178-91 [10683340.001]
  • [Cites] Semin Cancer Biol. 1999 Dec;9(6):387-95 [10712885.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):717-45 [12852653.001]
  • [Cites] Anticancer Res. 2003 May-Jun;23(3A):2133-8 [12894587.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5108-21 [12910248.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5122-30 [12910249.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6639-45 [14528289.001]
  • [Cites] Ann Med. 2003;35(6):404-12 [14572164.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15572-6 [14663138.001]
  • [Cites] AIDS Rev. 2003 Oct-Dec;5(4):222-9 [15012001.001]
  • [Cites] Oncogene. 2004 Mar 15;23(11):2107-15 [15021898.001]
  • [Cites] Nat Rev Cancer. 2004 May;4(5):349-60 [15122206.001]
  • [Cites] Mol Cell Biol. 2004 Jun;24(12):5089-93 [15169876.001]
  • [Cites] Curr Protein Pept Sci. 2004 Jun;5(3):153-61 [15180520.001]
  • [Cites] Oncologist. 2005 Aug;10(7):528-38 [16079320.001]
  • [Cites] Curr HIV/AIDS Rep. 2004 Apr;1(1):5-11 [16091217.001]
  • [Cites] Crit Rev Oncol Hematol. 2005 Oct;56(1):155-67 [15979320.001]
  • [Cites] Antivir Ther. 2005;10(6):745-51 [16218174.001]
  • [Cites] Essays Biochem. 2005;41:139-56 [16250903.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18431-6 [16344472.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18562-6 [16352731.001]
  • [Cites] Curr Opin Infect Dis. 2006 Feb;19(1):14-9 [16374212.001]
  • [Cites] Ann Pharm Fr. 2005 Sep;63(5):343-9 [16385784.001]
  • [Cites] Ann N Y Acad Sci. 2005 Nov;1056:328-43 [16387699.001]
  • [Cites] Annu Rev Med. 2006;57:33-47 [16409135.001]
  • [Cites] Expert Opin Investig Drugs. 2006 Feb;15(2):117-30 [16433592.001]
  • [Cites] Yonsei Med J. 2006 Feb 28;47(1):1-14 [16502480.001]
  • [Cites] Cancer Gene Ther. 2006 May;13(5):445-50 [16341140.001]
  • [Cites] Curr Med Chem. 2006;13(7):745-54 [16611064.001]
  • [Cites] Nihon Rinsho. 2006 Mar;64 Suppl 3:635-8 [16615550.001]
  • [Cites] Int J Oncol. 2000 May;16(5):853-70 [10762621.001]
  • [Cites] J Natl Cancer Inst. 2000 May 3;92(9):690-8 [10793105.001]
  • [Cites] Bioessays. 2000 May;22(5):442-51 [10797484.001]
  • [Cites] Clin Lab Med. 2000 Jun;20(2):383-406 [10863646.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):8051-6 [10859362.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4):390-401 [10950365.001]
  • [Cites] Adv Pharmacol. 2000;49:479-514 [11013772.001]
  • [Cites] Mol Cell Biol. 2000 Nov;20(22):8526-35 [11046148.001]
  • [Cites] Cell. 1990 Dec 21;63(6):1129-36 [2175676.001]
  • [Cites] Hum Cell. 1992 Mar;5(1):25-41 [1329931.001]
  • [Cites] MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19 [1361652.001]
  • [Cites] Princess Takamatsu Symp. 1991;22:239-48 [1668886.001]
  • [Cites] Int J Cancer. 1993 Sep 9;55(2):208-12 [8370617.001]
  • [Cites] Hosp Pract (1995). 1996 Sep 15;31(9):41-8, 53-5, 59-60 [8814120.001]
  • [Cites] Mol Med Today. 1997 Jun;3(6):246-53 [9211415.001]
  • [Cites] Semin Cancer Biol. 1996 Dec;7(6):317-26 [9284524.001]
  • [Cites] J Biol Chem. 1997 Nov 28;272(48):30135-40 [9374493.001]
  • [Cites] FEBS Lett. 1997 Dec 22;420(1):25-7 [9450543.001]
  • [Cites] J Biol Chem. 1998 Mar 13;273(11):6439-45 [9497376.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] Nature. 1998 Aug 6;394(6693):588-92 [9707121.001]
  • [Cites] Trends Microbiol. 1998 Jul;6(7):276-82 [9717216.001]
  • [Cites] Oncogene. 1998 Dec 10;17(23):2943-54 [9881696.001]
  • [Cites] Front Biosci. 1999 May 15;4:D468-75 [10331991.001]
  • (PMID = 18047745.001).
  • [ISSN] 1471-2091
  • [Journal-full-title] BMC biochemistry
  • [ISO-abbreviation] BMC Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Ubiquitin
  • [Number-of-references] 119
  • [Other-IDs] NLM/ PMC2106372
  •  go-up   go-down


27. Bonnet F, Chêne G: Evolving epidemiology of malignancies in HIV. Curr Opin Oncol; 2008 Sep;20(5):534-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evolving epidemiology of malignancies in HIV.
  • PURPOSE OF REVIEW: Morbidity and mortality related to malignancy are increasing in HIV-infected patients.
  • We aim at reviewing the literature on recent changes in the incidence of AIDS-defining and non-AIDS-defining malignancies and the specific characteristics of the main cancers emerging in HIV-infected patients.
  • RECENT FINDINGS: Currently, malignancies are the most frequent underlying cause of death (around one-third) of HIV-infected patients.
  • Since the introduction of combination antiretroviral therapy, the incidence of Kaposi's sarcoma and cerebral lymphoma (among AIDS-defining cancers) decreased in parallel with AIDS-defining infections, whereas the incidence of systemic non-Hodgkin's lymphoma and cervical cancer decreased less than others and remains higher in HIV-infected patients than in the general population.
  • The most recent and large studies have also shown a 1.7-3-fold higher risk of developing non-AIDS malignancies in HIV-infected patients as compared with the general population without a significant impact of combination antiretroviral therapy on these trends.
  • These malignancies include Hodgkin's disease, lung, anal, head and neck cancers, hemopathies, and conjunctival cancers.
  • In addition, the poorer prognosis reported in HIV-infected patients affected by malignancies might be interpreted as a consequence of late screening or immunosuppression.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106656.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 75
  •  go-up   go-down


28. Cummings JS, Cairo C, Armstrong C, Davis CE, Pauza CD: Impacts of HIV infection on Vgamma2Vdelta2 T cell phenotype and function: a mechanism for reduced tumor immunity in AIDS. J Leukoc Biol; 2008 Aug;84(2):371-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impacts of HIV infection on Vgamma2Vdelta2 T cell phenotype and function: a mechanism for reduced tumor immunity in AIDS.
  • These changes were common among 24 HIV+ patients and were not related to CD4 cell count or viral RNA burden.
  • Changes in Vgamma2Vdelta2 T cells, along with concomitant effects on NK and NKT cells that also contribute to tumor surveillance, may be important factors for elevating the risk of malignancy during AIDS.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Vaccine Immunol. 2007 Sep;14(9):1196-202 [17823271.001]
  • [Cites] J Exp Med. 2003 Aug 4;198(3):391-7 [12900516.001]
  • [Cites] J Reprod Immunol. 2008 Jul;78(2):85-93 [18243331.001]
  • [Cites] Annu Rev Immunol. 2000;18:975-1026 [10837080.001]
  • [Cites] J Biol Chem. 2001 Mar 9;276(10):6974-82 [11114298.001]
  • [Cites] Immunology. 2001 Sep;104(1):19-27 [11576216.001]
  • [Cites] J Leukoc Biol. 2001 Oct;70(4):518-26 [11590187.001]
  • [Cites] Clin Diagn Lab Immunol. 2001 Nov;8(6):1131-5 [11687452.001]
  • [Cites] Mol Med. 2001 Oct;7(10):711-22 [11713370.001]
  • [Cites] J Immunol. 2001 Dec 1;167(11):6195-201 [11714780.001]
  • [Cites] J Immunol. 2002 Feb 1;168(3):1484-9 [11801693.001]
  • [Cites] Trends Immunol. 2002 Jan;23(1):14-8 [11801449.001]
  • [Cites] J Biol Chem. 2002 May 31;277(22):19482-7 [11909874.001]
  • [Cites] J Virol. 2002 Aug;76(15):7528-34 [12097565.001]
  • [Cites] J Infect Dis. 2002 Sep 15;186(6):847-50 [12198622.001]
  • [Cites] AIDS Res Hum Retroviruses. 2003 Jan 1;19(1):21-9 [12581513.001]
  • [Cites] Trends Immunol. 2003 Apr;24(4):213-9 [12697454.001]
  • [Cites] Annu Rev Immunol. 1994;12:85-116 [8011300.001]
  • [Cites] J Immunol. 1994 Dec 15;153(12):5422-32 [7989747.001]
  • [Cites] J Clin Invest. 1995 May;95(5):2061-6 [7738173.001]
  • [Cites] Clin Exp Immunol. 1995 Nov;102(2):251-5 [7586674.001]
  • [Cites] Cytometry. 1995 Mar 15;22(1):10-5 [7587727.001]
  • [Cites] J Immunol. 1996 Jul 1;157(1):449-61 [8683151.001]
  • [Cites] Cell Immunol. 1996 Nov 25;174(1):19-24 [8929450.001]
  • [Cites] Mol Med. 1997 Jan;3(1):60-71 [9132281.001]
  • [Cites] J Exp Med. 1998 Apr 20;187(8):1295-303 [9547340.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] J Immunol. 2005 Oct 15;175(8):5471-80 [16210655.001]
  • [Cites] J Immunol. 2005 Oct 15;175(8):5481-8 [16210656.001]
  • [Cites] Immunology. 2006 Feb;117(2):145-55 [16423050.001]
  • [Cites] J Leukoc Biol. 2006 Apr;79(4):663-6 [16461739.001]
  • [Cites] J Immunol. 2006 Jun 15;176(12):7726-35 [16751420.001]
  • [Cites] J Infect Dis. 2007 Jan 1;195(1):37-45 [17152007.001]
  • [Cites] AIDS. 2007 Jan 11;21(2):207-13 [17197812.001]
  • [Cites] Cancer Immunol Immunother. 2007 Jun;56(6):819-29 [17131122.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]
  • [Cites] Immunol Lett. 2007 Jul 31;111(1):57-65 [17604848.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1801-7 [15178578.001]
  • [Cites] Int J Cancer. 1980 Sep 15;26(3):365-71 [6270007.001]
  • [Cites] Nature. 1987 Feb 19-25;325(6106):689-94 [3102967.001]
  • [Cites] Clin Exp Immunol. 1989 Feb;75(2):206-10 [2522839.001]
  • [Cites] Nouv Rev Fr Hematol. 1989;31(2):129-32 [2528119.001]
  • [Cites] J Exp Med. 1990 May 1;171(5):1567-79 [2185329.001]
  • [Cites] J Exp Med. 1990 May 1;171(5):1597-612 [2185330.001]
  • [Cites] J Acquir Immune Defic Syndr. 1990;3 Suppl 1:S38-43 [2395084.001]
  • [Cites] J Exp Med. 1991 Jun 1;173(6):1311-22 [1827824.001]
  • [Cites] Folia Biol (Praha). 1992;38(5):293-306 [1282473.001]
  • [Cites] Cell Immunol. 2007 Mar;246(1):8-16 [17574223.001]
  • [Cites] Clin Dev Immunol. 2007;2007:93462 [18317535.001]
  • (PMID = 18495780.001).
  • [ISSN] 0741-5400
  • [Journal-full-title] Journal of leukocyte biology
  • [ISO-abbreviation] J. Leukoc. Biol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA113261; United States / NIAID NIH HHS / AI / R21 AI051212; United States / NCI NIH HHS / CA / CA113261; United States / NIAID NIH HHS / AI / AI051212; United States / NIAID NIH HHS / AI / R01 AI051212
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD27; 0 / Antigens, CD95; 0 / Receptors, Antigen, T-Cell, gamma-delta; EC 3.1.3.48 / Antigens, CD45
  • [Other-IDs] NLM/ PMC2493077
  •  go-up   go-down


29. Ambinder RF, Bhatia K, Martinez-Maza O, Mitsuyasu R: Cancer biomarkers in HIV patients. Curr Opin HIV AIDS; 2010 Nov;5(6):531-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer biomarkers in HIV patients.
  • PURPOSE OF REVIEW: In this review, we update investigations related to cancer biomarkers in HIV-infected populations.
  • RECENT FINDINGS: CD4 lymphocyte count is associated with primary central nervous system lymphoma (PCNSL), systemic non-Hodgkin's lymphoma (NHL) (except perhaps for Burkitt lymphoma), Kaposi's sarcoma, cervical cancer, and anal cancer.
  • HIV load is associated with Burkitt lymphoma and systemic NHL (but not PCNSL), with Kaposi's sarcoma and with anal cancer.
  • Cytokines and related molecules (IL10, sCD30) may identify patients at high risk for NHL.
  • EBV and Kaposi's sarcoma-associated herpesvirus (KSHV) have not yet emerged as especially promising markers of risk for either lymphoma or Kaposi's sarcoma.
  • SUMMARY: CD4 lymphocyte count, HIV load, germline genetic polymorphisms, cytokine and related molecules, and immunoglobulin light chains all show increasing promise as biomarkers of malignancy in HIV patients.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AIDS. 2000 Jan 28;14(2):133-40 [10708283.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Nov;8(11):979-84 [10566552.001]
  • [Cites] Clin Immunol. 2003 Nov;109(2):119-29 [14597210.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2177-83 [15169806.001]
  • [Cites] Clin Infect Dis. 2004 Nov 1;39(9):1396-7; author reply 1397-8 [15494920.001]
  • [Cites] Blood. 1999 Mar 15;93(6):1838-42 [10068655.001]
  • [Cites] Cancer Res. 1999 Aug 1;59(15):3561-4 [10446961.001]
  • [Cites] Clin Immunol. 1999 Sep;92(3):293-9 [10479534.001]
  • [Cites] Gynecol Oncol. 2005 Mar;96(3):760-4 [15721423.001]
  • [Cites] Tumour Biol. 2006;27(4):187-94 [16651853.001]
  • [Cites] J Clin Virol. 2006 Aug;36(4):258-63 [16762591.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] Int J Infect Dis. 2007 Mar;11(2):172-8 [16931088.001]
  • [Cites] Clin Infect Dis. 2007 Jul 1;45(1):103-10 [17554710.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]
  • [Cites] PLoS Med. 2007 Mar 27;4(3):e96 [17388662.001]
  • [Cites] J Clin Virol. 2008 Aug;42(4):433-6 [18455472.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):884-90 [19114688.001]
  • [Cites] J Acquir Immune Defic Syndr. 2009 Apr 1;50(4):427-9 [19322036.001]
  • [Cites] PLoS One. 2009;4(4):e5360 [19390683.001]
  • [Cites] J Clin Oncol. 2009 May 20;27(15):2496-502 [19349542.001]
  • [Cites] Haematologica. 2009 Jun;94(6):875-80 [19336735.001]
  • [Cites] J Infect Dis. 2009 Jul 1;200(1):79-87 [19476437.001]
  • [Cites] Blood. 2009 Jun 4;113(23):5737-42 [19336755.001]
  • [Cites] J Natl Cancer Inst. 2009 Aug 19;101(16):1120-30 [19648510.001]
  • [Cites] Blood. 2009 Sep 10;114(11):2354; author reply 2354-5 [19745076.001]
  • [Cites] Blood. 2009 Sep 24;114(13):2730-2 [19638620.001]
  • [Cites] J Acquir Immune Defic Syndr. 2009 Dec;52(5):611-22 [19770804.001]
  • [Cites] Lancet Oncol. 2009 Dec;10(12):1152-9 [19818686.001]
  • [Cites] Am J Epidemiol. 2010 Feb 1;171(3):267-76 [20047977.001]
  • [Cites] J Acquir Immune Defic Syndr. 2009 Oct 1;52(2):170-9 [19654554.001]
  • [Cites] Biol Blood Marrow Transplant. 2010 Feb;16(2):287-91 [19835968.001]
  • [Cites] J Clin Oncol. 2010 Feb 10;28(5):773-9 [20048176.001]
  • [Cites] Leuk Lymphoma. 2010 Mar;51(3):497-506 [20038229.001]
  • [Cites] J Clin Oncol. 2010 Mar 20;28(9):1514-9 [20177022.001]
  • [Cites] AIDS. 2010 Apr 24;24(7):1025-33 [20299965.001]
  • [Cites] Cancer Causes Control. 2010 May;21(5):759-69 [20087644.001]
  • [Cites] J Acquir Immune Defic Syndr. 2010 May 1;54(1):78-84 [20418723.001]
  • [Cites] Sex Transm Dis. 2010 May;37(5):311-5 [20065890.001]
  • [Cites] J Natl Cancer Inst. 2010 Jun 2;102(11):784-92 [20442214.001]
  • [Cites] BMC Cancer. 2010;10:278 [20537184.001]
  • [Cites] Clin Infect Dis. 2010 Aug 1;51(3):342-9 [20572760.001]
  • [Cites] PLoS One. 2010;5(7):e11448 [20625427.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2730-4 [11023505.001]
  • (PMID = 20978397.001).
  • [ISSN] 1746-6318
  • [Journal-full-title] Current opinion in HIV and AIDS
  • [ISO-abbreviation] Curr Opin HIV AIDS
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA121947-05; United States / NCI NIH HHS / CA / CA096888-05S2; United States / NCI NIH HHS / CA / UO1 CA 121947; United States / NCI NIH HHS / CA / P50 CA096888-05S2; United States / NCI NIH HHS / CA / U01 CA121947; United States / NCI NIH HHS / CA / P50 CA096888
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ NIHMS274983; NLM/ PMC3055562
  •  go-up   go-down


30. Sloand E: Hematologic complications of HIV infection. AIDS Rev; 2005 Oct-Dec;7(4):187-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment of HIV-infected patients with highly active antiretroviral therapy (HAART) has altered the natural history of human immunodeficiency virus (HIV) infection by decreasing the frequency of opportunistic infections and altering the expected frequency of hematologic complications and AIDS-related malignancies.
  • [MeSH-minor] Anemia / drug therapy. Anemia / etiology. Antiretroviral Therapy, Highly Active. Humans. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / etiology. Neutropenia / drug therapy. Neutropenia / etiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Blood Disorders.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16425959.001).
  • [ISSN] 1139-6121
  • [Journal-full-title] AIDS reviews
  • [ISO-abbreviation] AIDS Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 105
  •  go-up   go-down


31. Lou J, Ruggeri T, Tebaldi C: Modeling cancer in hiv-1 infected individuals: equilibria, cycles and chaotic behavior. Math Biosci Eng; 2006 Apr;3(2):313-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modeling cancer in hiv-1 infected individuals: equilibria, cycles and chaotic behavior.
  • For HIV-infected individuals, cancer remains a significant burden.
  • Gaining insight into the epidemiology and mechanisms that underlie AIDS- related cancers can provide us with a better understanding of cancer immunity and viral oncogenesis.
  • In this paper, an HIV-1 dynamical model incorporat- ing the AIDS-related cancer cells was studied.
  • The model consists of three components, cancer cells, healthy CD4+ T lymphocytes and infected CD4+ T lymphocytes, and can have six steady states.
  • We discuss the existence, the stability properties and the biological meanings of these steady states, in par- ticular for the positive one: cancer-HIV-healthy cells steady state.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20361826.001).
  • [ISSN] 1547-1063
  • [Journal-full-title] Mathematical biosciences and engineering : MBE
  • [ISO-abbreviation] Math Biosci Eng
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Kiely B, O'Flaherty J, Surah S, Kieran J, O'Donnell D, Bergin C, Mulcahy F: HIV-related malignancies pre- and post-highly active antiretroviral therapy: experiences in an inner city tertiary referral centre. Int J STD AIDS; 2010 May;21(5):332-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-related malignancies pre- and post-highly active antiretroviral therapy: experiences in an inner city tertiary referral centre.
  • With highly active antiretroviral therapy (HAART), AIDS-defining malignancies are becoming less common.
  • The aim of this study was to review the demographics and outcomes of patients with cancer in the post-HAART era and to assess the impact of changing demographics and HAART through comparing them with previously published pre-HAART data from the same centre.
  • A retrospective chart review of 42 patients diagnosed with malignancy from 2000 to 2007 was performed and compared with pre-HAART (1987-1994) data.
  • The incidence of malignancies has decreased from 5.2% to 2.4%.
  • Non-AIDS-defining malignancies have increased and were associated with longer duration of HIV infection.
  • The change in patient demographics did not have an impact on the type of malignancies diagnosed.
  • Overall the incidence of malignancy has decreased; however, the increase in non-AIDS-defining malignancies highlights the importance of early diagnosis, use of HAART and prospective surveillance.


33. Cornejo-Juárez P, Volkow-Fernández P, Avilés-Salas A, Calderón-Flores E: AIDS and non-Hodgkin's lymphoma. Experience at an oncological center in Mexico. Rev Invest Clin; 2008 Sep-Oct;60(5):375-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS and non-Hodgkin's lymphoma. Experience at an oncological center in Mexico.
  • BACKGROUND: Non-Hodgkin lymphoma (NHL) associated with HIV became an AIDS-defining condition early in the epidemic and remains the second most common malignancy in patients with AIDS.
  • With the advent of highly active antiretroviral therapy (HAART), the incidence and mortality of AIDS-related opportunistic infections and Kaposi's sarcoma has fallen dramatically, this trend is not observed so clearly for NHL.
  • Our objective was to review the clinical spectrum of patients with AIDS-associated NHL and to analyze the impact of HAART on survival at an oncological tertiary center.
  • MATERIAL AND METHODS: We reviewed all medical records and histopathologic tissue of patients with HIV-associated NHL seen from January 1990 to September 2007 at the Instituto Nacional de Cancerologia in Mexico City.
  • [MeSH-major] Cancer Care Facilities / statistics & numerical data. Lymphoma, AIDS-Related / epidemiology. Lymphoma, Large B-Cell, Diffuse / epidemiology. Lymphoma, Non-Hodgkin / epidemiology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19227434.001).
  • [ISSN] 0034-8376
  • [Journal-full-title] Revista de investigación clínica; organo del Hospital de Enfermedades de la Nutrición
  • [ISO-abbreviation] Rev. Invest. Clin.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


34. Wang X, Wang X, Liang D, Lan K, Guo W, Ren G: Classic Kaposi's sarcoma in Han Chinese and useful tools for differential diagnosis. Oral Oncol; 2010 Sep;46(9):654-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kaposi's sarcoma (KS) is a common AIDS-related malignant neoplasm in the head and neck region, especially in the oral cavity, but is rarely described in the HIV-negative and non-immunosuppressed individual.

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20656545.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


36. Brinker BT, Krown SE, Lee JY, Cesarman E, Chadburn A, Kaplan LD, Henry DH, Von Roenn JH: Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS Malignancy Consortium. Cancer; 2008 Mar 1;112(5):1083-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS Malignancy Consortium.
  • The safety and efficacy of a novel, orally bioavailable MMP inhibitor, BMS-275291, was evaluated in patients with human immunodeficiency virus-associated KS and the correlation between changes in the percentage of apoptotic cells in tumor biopsies and response was explored.
  • A DLT occurred in 3 patients treated with 600 mg twice daily, and included grade 3 fatigue, grade 3 allergic reaction, and grade 3 arthralgias; 2 responses were noted at this dose level (toxicity was graded according to the National Cancer Institute Common Toxicity Criteria [version 2.0]).
  • The better-tolerated schedule of 1200 mg once a day demonstrated inadequate efficacy in patients with human immunodeficiency virus-associated KS.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer. 2008 Mar 1;112(5):962-5 [18098222.001]
  • (PMID = 18224669.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01 CA 070019; United States / NCI NIH HHS / CA / U01 CA 070047; United States / NCI NIH HHS / CA / U01 CA 070054; United States / NCI NIH HHS / CA / U01 CA 070058; United States / NCI NIH HHS / CA / U01 CA 070062; United States / NCI NIH HHS / CA / U01 CA 070079; United States / NCI NIH HHS / CA / U01 CA 083038; United States / NCI NIH HHS / CA / U01 CA 121947
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Imidazoles; 0 / Matrix Metalloproteinase Inhibitors; 259188-38-0 / N-((2S)-2-mercapto-1-oxo-4-(3,4,4- trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-L-leucyl-N,3- dimethyl-L-Valinamide
  •  go-up   go-down


37. Tasaka S, Tokuda H, Sakai F, Fujii T, Tateda K, Johkoh T, Ohmagari N, Ohta H, Araoka H, Kikuchi Y, Yasui M, Inuzuka K, Goto H: Comparison of clinical and radiological features of pneumocystis pneumonia between malignancy cases and acquired immunodeficiency syndrome cases: a multicenter study. Intern Med; 2010;49(4):273-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of clinical and radiological features of pneumocystis pneumonia between malignancy cases and acquired immunodeficiency syndrome cases: a multicenter study.
  • Although PCP in patients with acquired immunodeficiency syndrome (AIDS) has been extensively described, its characteristics in non-AIDS patients, such as those with malignancies, are not thoroughly documented.
  • STUDY OBJECTIVE: To characterize and compare the clinical and imaging features of PCP in patients with malignancies with those in AIDS patients.
  • PATIENTS AND MEASUREMENTS: We evaluated the clinical and radiological features of PCP in 21 patients with malignancies and in 17 with AIDS.
  • RESULTS: The patients with malignancies showed shorter durations of symptoms before PCP was diagnosed.
  • None of the AIDS patients demonstrated consolidation, whereas half of the patients with malignancy showed consolidation along with GGO.
  • The extent of GGO scored on CT images was significantly greater in the AIDS patients.
  • All of the AIDS patients recovered from PCP, whereas six patients with malignancies died within a month after the onset of PCP.
  • CONCLUSION: The characteristics of the CT images differed between the patient groups with different underlying disorders, although it remains to be determined whether CT findings are associated with other clinical features or are predictive of the outcome of PCP.
  • [MeSH-major] AIDS-Related Opportunistic Infections / diagnosis. Neoplasms / complications. Pneumonia, Pneumocystis / diagnosis. Pneumonia, Pneumocystis / etiology

  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • Hazardous Substances Data Bank. OXYGEN .
  • Hazardous Substances Data Bank. TRIMETHOPRIM/SULFAMETHOXAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20154431.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 0 / Biomarkers; 8064-90-2 / Trimethoprim, Sulfamethoxazole Drug Combination; S88TT14065 / Oxygen
  •  go-up   go-down


38. Biggar RJ, Engels EA, Ly S, Kahn A, Schymura MJ, Sackoff J, Virgo P, Pfeiffer RM: Survival after cancer diagnosis in persons with AIDS. J Acquir Immune Defic Syndr; 2005 Jul 1;39(3):293-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival after cancer diagnosis in persons with AIDS.
  • The survival of persons with AIDS (PWA) has recently improved because of better antiretroviral therapies.
  • Similarly, the prognosis of cancer has also improved.
  • To determine if survival in PWA with cancer has also improved, we compared cancer survival in adults with and without AIDS using data from New York City from 1980 through 2000.
  • Analyses were made for AIDS-related cancers (Kaposi sarcoma, non-Hodgkin lymphoma [NHL], and cervical cancer) and for 8 non-AIDS-related cancers (lung, larynx, colorectum, anus, Hodgkin lymphoma, breast, prostate, and testis).
  • Death hazard ratios compared survival in PWA with cancer with that in cancer patients without AIDS, adjusted for age, sex, race, and calendar-time of cancer occurrence.
  • The 24-month survival rate of PWA with cancer (9015 AIDS cancers and 929 non-AIDS-related cancers of 8 types) improved significantly for most cancer types.
  • By 1996 through 2000, the 24-month survival rate in PWA was 58% for Kaposi sarcoma, 41% for peripheral NHL, 29% for central nervous system NHL, and 64% for cervical cancer.
  • For non-AIDS-related cancers, survival of PWA was lowest for lung cancer (10%) but was >50% for most other cancer types.
  • In 1996 through 2000, significant differences in survival between cancer patients with and without AIDS still remained for Hodgkin lymphoma and lung, larynx, and prostate cancers.
  • We conclude that recent improvements in AIDS and cancer care have greatly narrowed the gap in survival between cancer patients with and without AIDS.
  • Clinicians should be encouraged by the improving prognosis and be diligent about detecting and treating cancer in PWA.
  • [MeSH-minor] Antiretroviral Therapy, Highly Active. Female. Humans. Lymphoma, AIDS-Related / mortality. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / mortality. Male. New York City / epidemiology. Prognosis. Registries. Sarcoma, Kaposi / complications. Sarcoma, Kaposi / mortality. Survival Rate

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15980688.001).
  • [ISSN] 1525-4135
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Makombe SD, Harries AD, Yu JK, Hochgesang M, Mhango E, Weigel R, Pasulani O, Fitzgerald M, Schouten EJ, Libamba E: Outcomes of patients with Kaposi's sarcoma who start antiretroviral therapy under routine programme conditions in Malawi. Trop Doct; 2008 Jan;38(1):5-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIDS-associated Kaposi's sarcoma (KS) is the most common AIDS-related malignancy in sub-Saharan Africa, with a generally unfavourable prognosis.


40. Schlichemeyer R, Chambers C, Gill MJ: The oncology impact of highly active antiretroviral therapy. J Oncol Pharm Pract; 2007 Mar;13(1):17-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To examine the impact of using highly active antiretroviral therapy (HAART) in a human immunodeficiency virus (HIV) infected population on the chemotherapy related costs of treating acquired immunodeficiency (AIDS)-related cancers.
  • METHODS: We used the Southern Alberta Clinic (SAC) database to define the incidence and prevalence of AIDS-related cancers in a geographically defined HIV population in both the pre- HAART and HAART eras, and subsequently, the Alberta Cancer Board Pharmacy database to determine the chemotherapy associated costs of the cancer treatment.
  • RESULTS: During both eras, 60% of AIDS-related cancer patients received chemotherapy.
  • The absolute number of patients treated in the pre-HAART era was 70, but during the HAART era, due to the decreased incidence of these cancers, only 13 patients received chemotherapy.
  • The number of distinct regimens used for AIDS cancer treatment standardised, and decreased from 29 to six between eras.
  • CONCLUSION: The introduction of HAART has dramatically reduced the amount spent on chemotherapy due to a decreased incidence of AIDSrelated cancers, even though the individual patient treatments have become more effective and expensive.

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17621563.001).
  • [ISSN] 1078-1552
  • [Journal-full-title] Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
  • [ISO-abbreviation] J Oncol Pharm Pract
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


41. Noy A, Scadden DT, Lee J, Dezube BJ, Aboulafia D, Tulpule A, Walmsley S, Gill P: Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team. J Clin Oncol; 2005 Feb 10;23(5):990-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team.
  • Phase I/II studies showed minimal toxicity and a response rate of 36% in AIDS-Kaposi's sarcoma.
  • However, IM862 was associated with both a shorter time to response (8.5 weeks v 14 weeks; P = .024) and shorter median time to progression (16 weeks, 95% CI, 13 to 27 weeks v 35 weeks, 95% CI, 26 to 114 weeks; P = .012).
  • Highly active antiretroviral therapy alone was associated with a substantial rate of sustained tumor response and may have contributed to prior estimates of IM862 response.
  • Therapeutic trials for AIDS-Kaposi's sarcoma must account for ongoing immune reconstitution in the setting of concurrent highly active antiretroviral therapy that may confound estimates of therapeutic activity.
  • [MeSH-major] AIDS-Related Opportunistic Infections / drug therapy. Acquired Immunodeficiency Syndrome / drug therapy. Angiogenesis Inhibitors / therapeutic use. Anti-HIV Agents / therapeutic use. Dipeptides / therapeutic use. Sarcoma, Kaposi / drug therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Clinical Implications of Immune Reconstitution in AIDS .
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15598977.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01CA070019; United States / NCI NIH HHS / CA / U01CA070047; United States / NCI NIH HHS / CA / U01CA070054; United States / NCI NIH HHS / CA / U01CA070068; United States / NCI NIH HHS / CA / U01CA070072; United States / NCI NIH HHS / CA / U01CA070075; United States / NCI NIH HHS / CA / U01CA070079; United States / NCI NIH HHS / CA / U01CA070080; United States / NCI NIH HHS / CA / U01CA070081; United States / NCI NIH HHS / CA / U01CA071375; United States / NCI NIH HHS / CA / U01CA083038; United States / NCI NIH HHS / CA / U01CA083118; United States / NCI NIH HHS / CA / U01CA70062; United States / NCI NIH HHS / CA / U01CA83035
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Anti-HIV Agents; 0 / Dipeptides; 0 / Placebos; 122933-59-9 / thymogen
  •  go-up   go-down


42. Taiwo B, Hicks C, Eron J: Unmet therapeutic needs in the new era of combination antiretroviral therapy for HIV-1. J Antimicrob Chemother; 2010 Jun;65(6):1100-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The need for new or enhanced cART may become increasingly apparent as patients live longer with HIV and a greater proportion die from non-AIDS-related illnesses.
  • In addition, neurocognitive impairment and malignancy are important sources of ongoing morbidity despite cART.
  • [MeSH-minor] AIDS Dementia Complex / drug therapy. AIDS Dementia Complex / epidemiology. Comorbidity. HIV-Associated Lipodystrophy Syndrome / drug therapy. HIV-Associated Lipodystrophy Syndrome / epidemiology. Humans. Neoplasms / drug therapy. Neoplasms / epidemiology


43. Yarchoan R, Pluda JM, Wyvill KM, Aleman K, Rodriguez-Chavez IR, Tosato G, Catanzaro AT, Steinberg SM, Little RF: Treatment of AIDS-related Kaposi's sarcoma with interleukin-12: rationale and preliminary evidence of clinical activity. Crit Rev Immunol; 2007;27(5):401-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of AIDS-related Kaposi's sarcoma with interleukin-12: rationale and preliminary evidence of clinical activity.
  • In addition, it can downregulate a constitutively active G protein coupled receptor that is encoded by Kaposi's sarcoma-associated herpesvirus, the causative agent of KS.
  • In an initial phase I pilot study, IL-12 was found to have anti-KS activity when used alone in patients with AIDS-associated KS who were on a stable regimen of antiretroviral therapy.
  • In preliminary results from a subsequent study of the combination of IL-12 plus liposomal doxorubicin along with highly active antiretroviral therapy, remissions were obtained in a substantial percentage of patients with advanced AIDS-associated KS.
  • [MeSH-major] AIDS-Related Opportunistic Infections / drug therapy. HIV Infections / drug therapy. Interleukin-12 / therapeutic use. Sarcoma, Kaposi / drug therapy


44. Magrath I: Lessons from clinical trials in African Burkitt lymphoma. Curr Opin Oncol; 2009 Sep;21(5):462-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE OF REVIEW: The center of gravity of the AIDS epidemic has moved - in 2007, 67% of all persons living with HIV infection and 72% of all deaths from AIDS occurred in Africa.
  • The present review focuses on the treatment of an AIDS-defining malignancy, Burkitt lymphoma, since the discovery of the tumor in 1958 to provide a backdrop to the increasing necessity of dealing with AIDS-associated Burkitt lymphoma in Africa.
  • RECENT FINDINGS: In Africa, it appears that AIDS-associated Burkitt lymphoma is increasing, but although treatment outcome is presently poor, the demonstration that highly active antiretroviral therapy permits the same treatment results to those in AIDS-unassociated Burkitt lymphoma provides hope for the future.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, AIDS-Related / drug therapy

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19620863.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 64
  •  go-up   go-down


45. Theodoropoulos G, Papaconstantinou I, Felekouras E, Nikiteas N, Karakitsos P, Panoussopoulos D, Lazaris ACh, Patsouris E, Bramis J, Gazouli M: Relation between common polymorphisms in genes related to inflammatory response and colorectal cancer. World J Gastroenterol; 2006 Aug 21;12(31):5037-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relation between common polymorphisms in genes related to inflammatory response and colorectal cancer.
  • AIM: To investigate the association between common single nucleotide polymorphisms (SNPs) in inflammatory response-related genes such as interleukin (IL)-6, IL-8, tumor necrosis factor alpha (TNFalpha), peroxisome proliferators-activated receptor gamma (PPARgamma), intercellular adhesion molecule-1 (ICAM-1) and the risk of colorectal cancer (CRC) in a group of Greek patients.
  • RESULTS: The IL-6 -174G, R241 and K469 alleles of ICAM-1 were associated with increased risk of CRC (OR = 1.77, 95% CI: 1.34-2.34; OR = 1.83, 95% CI: 1.23-2.72; and OR = 1.35, 95% CI: 1.03-1.77 respectively).
  • Whereas the PPARgamma Pro12 genotype was associated with increased risk of disease (OR = 1.78, 95% CI: 1.25-2.49).
  • CONCLUSION: The association between common SNPs in immunologic response-related genes and CRC is reported in the present study.
  • Apart from shedding light on the mechanisms of malignancy initiation and progression, SNPs may improve appropriate screening for sub-populations at risk.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Exp Gerontol. 2002 Jan-Mar;37(2-3):309-14 [11772517.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):499-508 [9053471.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Feb;87(2):772-5 [11836319.001]
  • [Cites] Eur J Immunogenet. 2002 Feb;29(1):7-10 [11841482.001]
  • [Cites] Life Sci. 2002 Feb 15;70(13):1565-75 [11895107.001]
  • [Cites] Cardiovasc Res. 2002 Mar;53(4):1029-34 [11922913.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2002 Apr;16(2):171-85 [11969232.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3369-72 [12067976.001]
  • [Cites] Br Med Bull. 2002;64:27-43 [12421723.001]
  • [Cites] J Natl Cancer Inst. 2002 Nov 20;94(22):1680-7 [12441323.001]
  • [Cites] Gut. 2003 Jan;52(1):75-8 [12477764.001]
  • [Cites] Mol Hum Reprod. 2003 Jan;9(1):47-52 [12529420.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jan 31;301(1):50-3 [12535639.001]
  • [Cites] Eur J Immunogenet. 1998 Apr-Jun;25(2-3):267 [9615916.001]
  • [Cites] Mol Cells. 1998 Apr 30;8(2):246-9 [9638659.001]
  • [Cites] Nat Med. 1998 Sep;4(9):1046-52 [9734398.001]
  • [Cites] J Clin Invest. 1998 Oct 1;102(7):1369-76 [9769329.001]
  • [Cites] Jpn J Cancer Res. 1999 Jan;90(1):75-80 [10076568.001]
  • [Cites] Mol Cell. 1999 Jun;3(6):799-804 [10394368.001]
  • [Cites] Carcinogenesis. 2005 Mar;26(3):579-85 [15564289.001]
  • [Cites] Cancer Lett. 2003 Feb 28;191(1):67-74 [12609711.001]
  • [Cites] Gastroenterology. 2003 May;124(5):1193-201 [12730860.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):2173-6 [12796383.001]
  • [Cites] J Pharmacol Sci. 2003 May;92(1):7-12 [12832849.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3560-6 [12839942.001]
  • [Cites] Gastroenterology. 2003 Aug;125(2):364-71 [12891537.001]
  • [Cites] Gut. 2003 Sep;52(9):1317-22 [12912864.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):11-22 [14708024.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Apr;286(4):G515-20 [15010360.001]
  • [Cites] Anticancer Res. 2004 Mar-Apr;24(2C):1311-4 [15154666.001]
  • [Cites] Hum Mol Genet. 1992 Aug;1(5):353 [1363876.001]
  • [Cites] Int J Cancer. 1994 Jul 1;58(1):80-4 [7516927.001]
  • [Cites] Genomics. 1994 Jun;21(3):473-7 [7525451.001]
  • [Cites] Aliment Pharmacol Ther. 2000 Apr;14 Suppl 1:64-7 [10807405.001]
  • [Cites] J Biol Chem. 2000 Jun 16;275(24):18138-44 [10747905.001]
  • [Cites] J Med Genet. 2000 Jun;37(6):410-4 [10851250.001]
  • [Cites] Free Radic Biol Med. 2000 May 1;28(9):1379-86 [10924857.001]
  • [Cites] Nat Genet. 2000 Sep;26(1):76-80 [10973253.001]
  • [Cites] J Natl Cancer Inst. 2000 Oct 4;92(19):1592-600 [11018095.001]
  • [Cites] Thorax. 2000 Dec;55(12):1023-7 [11083887.001]
  • [Cites] Hepatogastroenterology. 2001 Mar-Apr;48(38):468-70 [11379335.001]
  • [Cites] Curr Biol. 2001 May 15;11(10):764-8 [11378386.001]
  • [Cites] Eur J Immunol. 2001 Aug;31(8):2357-61 [11500818.001]
  • [Cites] Trends Mol Med. 2001 Aug;7(8):329-31 [11516972.001]
  • [Cites] Curr Gastroenterol Rep. 2001 Oct;3(5):392-8 [11560796.001]
  • [Cites] Clin Immunol. 2001 Dec;101(3):357-60 [11726228.001]
  • [Cites] Gastroenterology. 1995 Aug;109(2):440-8 [7615193.001]
  • [Cites] J Biol Chem. 1995 Oct 13;270(41):23975-83 [7592593.001]
  • [Cites] AIDS. 1995 Nov;9(11):1295-6 [8561992.001]
  • [Cites] Semin Surg Oncol. 1995 Nov-Dec;11(6):399-405 [8607008.001]
  • [Cites] J Biol Chem. 1997 Feb 7;272(6):3406-10 [9013583.001]
  • [Cites] Trends Mol Med. 2002 Jan;8(1):10-6 [11796261.001]
  • (PMID = 16937502.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Interleukin-6; 0 / Interleukin-8; 0 / PPAR gamma; 0 / Tumor Necrosis Factor-alpha; 126547-89-5 / Intercellular Adhesion Molecule-1
  • [Other-IDs] NLM/ PMC4087409
  •  go-up   go-down


46. Reese PP, Blumberg EA, Bloom RD: Kidney transplantation in patients with HIV infection. Adv Chronic Kidney Dis; 2010 Jan;17(1):94-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Long-term follow-up studies will be important to examine these outcomes and the development of malignancy to fully evaluate the risk and benefits of kidney transplantation among HIV-positive recipients.
  • [MeSH-major] AIDS-Related Opportunistic Infections / complications. Graft Rejection / etiology. HIV Infections / complications. Kidney Failure, Chronic / complications. Kidney Failure, Chronic / surgery. Kidney Transplantation


47. Zeng Y, Li Y, Chen RS, He X, Yang L, Li W: Overexpression of xCT induces up-regulation of 14-3-3beta in Kaposi's sarcoma. Biosci Rep; 2010 Aug;30(4):277-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • KSHV (Kaposi's sarcoma-associated herpesvirus), or HHV-8 (human herpesvirus 8), is associated with the pathogenesis of KS, the most common AIDS-related malignancy. xCT (functional subunit of the cystine/glutamate transporter xc- system) is known as the HHV-8 fusion-entry receptor as well as an oncogenic protein.

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2000 Apr 6;342(14):1027-38 [10749966.001]
  • [Cites] Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2000 Mar;14(1):44-6 [11503024.001]
  • [Cites] Antioxid Redox Signal. 2000 Winter;2(4):665-71 [11213471.001]
  • [Cites] J Biol Chem. 2001 Mar 23;276(12):8746-52 [11121428.001]
  • [Cites] Biochim Biophys Acta. 2001 Jun 6;1512(2):335-44 [11406111.001]
  • [Cites] Bioessays. 2001 Oct;23(10):936-46 [11598960.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] FEMS Microbiol Lett. 2003 May 28;222(2):155-63 [12770701.001]
  • [Cites] Cancer Surv. 1991;10:5-22 [1821323.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] FASEB J. 1995 Jun;9(9):726-35 [7601337.001]
  • [Cites] Virology. 1997 Nov 10;238(1):22-9 [9375005.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):355-60 [15625115.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):10964-9 [16037214.001]
  • [Cites] Science. 2006 Mar 31;311(5769):1921-4 [16574866.001]
  • [Cites] J Virol. 2006 Jul;80(13):6534-52 [16775340.001]
  • [Cites] J Virol. 2007 Aug;81(15):7941-59 [17507466.001]
  • [Cites] J Cell Physiol. 2008 Jun;215(3):593-602 [18181196.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Jun 13;370(4):584-8 [18395005.001]
  • [Cites] BMC Cancer. 2008;8:350 [19036168.001]
  • [Cites] Oncogene. 2009 Jan 29;28(4):599-609 [19015640.001]
  • [Cites] Biochem J. 2000 May 1;347 Pt 3:781-5 [10769183.001]
  • (PMID = 20100173.001).
  • [ISSN] 1573-4935
  • [Journal-full-title] Bioscience reports
  • [ISO-abbreviation] Biosci. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 14-3-3 Proteins; 0 / Amino Acid Transport System y+; 0 / SLC7A11 protein, human; 0 / Slc7a11 protein, mouse
  • [Other-IDs] NLM/ PMC2860696
  •  go-up   go-down


48. Zhang JA, Anyarambhatla G, Ma L, Ugwu S, Xuan T, Sardone T, Ahmad I: Development and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation. Eur J Pharm Biopharm; 2005 Jan;59(1):177-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Taxol is a marketed product for the treatment of ovarian, breast, non-small cell lung cancer and AIDS-related Kaposi's Sarcoma.

  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. GLYCERIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15567316.001).
  • [ISSN] 0939-6411
  • [Journal-full-title] European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V
  • [ISO-abbreviation] Eur J Pharm Biopharm
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Liposomes; 0 / Pharmaceutical Vehicles; 0 / Solvents; 6D4M1DAL6O / cremophor EL; P88XT4IS4D / Paclitaxel; PDC6A3C0OX / Glycerol
  •  go-up   go-down


49. Orem J, Otieno MW, Remick SC: Challenges and opportunities for treatment and research of AIDS-related malignancies in Africa. Curr Opin Oncol; 2006 Sep;18(5):479-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Challenges and opportunities for treatment and research of AIDS-related malignancies in Africa.
  • PURPOSE OF REVIEW: Following our review of AIDS-associated cancer in developing nations in 2004, we sought to update recent publications and review data on the challenges and opportunities for the treatment and research of AIDS malignancies in Africa.
  • RECENT FINDINGS: It is apparent that the burden of AIDS-related malignancies and other virus-associated tumors is significant and increasing in Africa.
  • Several recent studies report findings on conjunctival squamous cell carcinoma and there is a report that Hodgkin's disease, a non-AIDS-defining neoplasm, is increasing in incidence.
  • International collaborative partnerships dedicated to AIDS malignancies in developing countries are feasible and invaluable for clinical strategies to address this aspect of the pandemic.
  • A departure point is the ongoing work of the East Africa - Case Western Reserve University Collaboration in AIDS malignancies.
  • SUMMARY: The burden of neoplastic complications of HIV infection and endemic virus-associated tumors are assuming increasing significance in Africa.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16894296.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI36219; United States / NCI NIH HHS / CA / CA43703; United States / NCI NIH HHS / CA / CA70081; United States / NCI NIH HHS / CA / CA83528; United States / FIC NIH HHS / TW / TW00011
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Number-of-references] 56
  •  go-up   go-down


50. Arora A, Chiao E, Tyring SK: AIDS malignancies. Cancer Treat Res; 2007;133:21-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS malignancies.
  • Among individuals with HIV-infection, coinfection with oncogenic viruses including EBV, HHV-8, and HPV cause significant cancer-related morbidity and mortality.
  • It is clear that these viruses interact with HIV in unique ways that predispose HIV-infected individuals to malignant diseases.
  • In general, treatment directed specifically against these viruses does not appear to change the natural history of the malignant disease, and once the malignancy develops, if their health permits, HIV-infected patients should be treated using similar treatment protocols to HIV-negative patients.
  • However, for the less frequent HIV-related malignancies, such as PEL, or MCD, optimal treatments are still emerging.
  • For certain AIDS-defining malignancies, it is clear that the widespread access to HAART has significantly decreased the incidence, and improved outcomes.
  • However, for other cancers, such as the HPV-related tumors, the role of HAART is much less clear.
  • Further research into prevention and treatment of these oncogenic virally mediated AIDS-related malignancies is necessary.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17672037.001).
  • [ISSN] 0927-3042
  • [Journal-full-title] Cancer treatment and research
  • [ISO-abbreviation] Cancer Treat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 368
  •  go-up   go-down


51. Siemieniuk E, Skrzydlewska E: [Coenzyme Q10: its biosynthesis and biological significance in animal organisms and in humans]. Postepy Hig Med Dosw (Online); 2005;59:150-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Decreased levels of coenzyme Q10 in humans are observed in many pathologies (e.g. cardiac disorders, neurodegenerative diseases, AIDS, cancer) associated with intensive generation of free radicals and their action on cells and tissues.

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15928598.001).
  • [ISSN] 1732-2693
  • [Journal-full-title] Postepy higieny i medycyny doswiadczalnej (Online)
  • [ISO-abbreviation] Postepy Hig Med Dosw (Online)
  • [Language] POL
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Coenzymes; 0 / Free Radicals; 1339-63-5 / Ubiquinone; EJ27X76M46 / coenzyme Q10
  • [Number-of-references] 57
  •  go-up   go-down


52. Gichuhi S, Irlam JJ: Interventions for squamous cell carcinoma of the conjunctiva in HIV-infected individuals. Cochrane Database Syst Rev; 2007;(2):CD005643
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This pattern is related to the co-existence of the HIV/AIDS pandemic, high HPV exposure, and solar radiation in the region.
  • SEARCH STRATEGY: Using a sensitive search strategy, we attempted to identify all relevant trials, regardless of language or publication status, from the following electronic databases; Medline/PubMed, CENTRAL, AIDSearch, EMBASE, LILACS, African Healthline, Cochrane HIV/AIDS Specialised Register, and the Cochrane Cancer Network Specialised Register.
  • We searched the clinical trial register of the US National Institutes of Health, searched the international conference proceedings of AIDS and AIDS-related cancers, and contacted individual researchers, research organisations, and pharmaceutical companies that manufacture the drugs used as interventions.
  • HIV/AIDS research has not focused on treatment of this tumour.


53. Ramon I, Libert M, Guillaume MP, Corazza F, Karmali R: Recurrent haemophagocytic syndrome in an HIV-infected patient. Acta Clin Belg; 2010 Jul-Aug;65(4):276-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe a case of recurrent haemophagocytic syndrome (HS) in an HIV-infected patient.The first episode was associated with active human herpesvirus 8 infection and progressive Kaposi's sarcoma which was successfully treated with splenectomy, foscarnet and chemotherapy.
  • Recurrent HS has rarely been described in adult patients out of the setting of relapsing malignancy or autoimmune disease.The chronic immune dysregulation and suppression due to HIV-infection may predispose our patient to development of associated HS.
  • [MeSH-major] AIDS-Related Opportunistic Infections / diagnosis. Lymphohistiocytosis, Hemophagocytic / diagnosis. Sarcoma, Kaposi / diagnosis

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20954469.001).
  • [ISSN] 1784-3286
  • [Journal-full-title] Acta clinica Belgica
  • [ISO-abbreviation] Acta Clin Belg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


54. Martí-Carvajal AJ, Cardona AF, Rodríguez ML: Interventions for treating AIDS-associated Hodgkin s lymphoma in treatment-naive adults. Cochrane Database Syst Rev; 2007;(2):CD006149
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interventions for treating AIDS-associated Hodgkin s lymphoma in treatment-naive adults.
  • BACKGROUND: Hodgkin's disease (HD) is the most common non-AIDS-defining malignancy in HIV-infected patients.
  • Thus, there is a need to identify the efficacy and safety of different interventions for AIDS-associated HD on overall survival and disease-free survival in treatment-naive adults with AIDS.
  • OBJECTIVES: To assess the effects of different interventions for treating AIDS-associated Hodgkin's disease including chemotherapy, bone marrow transplantation (BMT), and gene therapy on overall survival and disease-free survival in treatment-naive adults with AIDS.
  • SEARCH STRATEGY: We searched The Cochrane HIV/AIDS Group Trials Register (September 2006), which comprises references identified from comprehensive electronic database searches and handsearching of relevant journals and abstract books of conference proceedings.
  • MAIN RESULTS: We were unable to find any randomised controlled trials of interventions for treating AIDS-associated HD in treatment-naive adults with AIDS.
  • AUTHORS' CONCLUSIONS: Randomised controlled trials are needed to establish the efficacy and safety of interventions for treating AIDS-associated HD in treatment-naive adults with AIDS.
  • [MeSH-major] Lymphoma, AIDS-Related / therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17443616.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 75
  •  go-up   go-down


55. Cadogan M, Dalgleish AG: HIV induced AIDS and related cancers: chronic immune activation and future therapeutic strategies. Adv Cancer Res; 2008;101:349-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV induced AIDS and related cancers: chronic immune activation and future therapeutic strategies.
  • Chronic generalized immune activation represents one of the most critical features determining progression to AIDS.
  • This may result in the manifestation of malignancy, with lymphoma and Karposi's sarcoma being the first to be recognised.
  • Despite a lifecycle adapted to the host and possessing a plethora of survival strategies, HIV promotes disease progression in a manner that is consistently associated with the HLA repertoire suggesting pathogenic features relating to immunological incompatibility may be at the root of disease.
  • Here we review the influence of immune activation on progression to AIDS with particular reference to molecular mimicry and autoimmune phenomenon and highlight the therapeutic potential of non-neutralizing antibodies and strategies designed to diffuse immune activation.
  • [MeSH-minor] AIDS-Related Opportunistic Infections / etiology. Alleles. Amino Acid Sequence. Animals. Disease Progression. Disease Susceptibility. HLA Antigens / chemistry. Humans. Immune System. Molecular Sequence Data. Sequence Homology, Amino Acid. Treatment Outcome

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19055948.001).
  • [ISSN] 0065-230X
  • [Journal-full-title] Advances in cancer research
  • [ISO-abbreviation] Adv. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA Antigens
  • [Number-of-references] 350
  •  go-up   go-down


56. Hiatt KM, Nelson AM, Lichy JH, Fanburg-Smith JC: Classic Kaposi Sarcoma in the United States over the last two decades: a clinicopathologic and molecular study of 438 non-HIV-related Kaposi Sarcoma patients with comparison to HIV-related Kaposi Sarcoma. Mod Pathol; 2008 May;21(5):572-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Classic Kaposi Sarcoma in the United States over the last two decades: a clinicopathologic and molecular study of 438 non-HIV-related Kaposi Sarcoma patients with comparison to HIV-related Kaposi Sarcoma.
  • Since the emergence of acquired immune deficiency syndrome (AIDS)-related Kaposi sarcoma, the incidence, clinicopathologic features, and molecular human herpesvirus 8 (HHV-8) association of American Classic Kaposi Sarcoma has not been fully explored.
  • This study compares Classic Kaposi Sarcoma to AIDS-related Kaposi Sarcoma over the same two decade time period.
  • A second, non-Classic Kaposi Sarcoma, malignancy was present in 42% (n=45) of the 108 Classic Kaposi Sarcoma patients with complete clinical information, 73% (33 patients) with a higher incidence over the general population.
  • Follow-up of <1-19 years (mean=4.8 years) revealed that 24% of patients died of second malignancy, 22% died of other medical conditions, 2% died of treatment-related complications, and 2% patients died of widespread disease.
  • Human immunodeficiency virus-related Kaposi Sarcoma was observed in 354 cases.
  • While Classic Kaposi Sarcoma in the United States is an indolent disease and rarely accounts for patient demise, predominantly affecting Caucasian/American males on the lower extremity in the nodular phase, it more importantly may denote an underlying other malignancy.
  • In comparison, AIDS-related Kaposi Sarcoma is predominately multicentric, visceral, and disseminated, with more aggressive behavior.


57. Sampaio J, Brites C, Araujo I, Bacchi CE, Dittmer DP, Tanaka PY, Harrington W Jr, Netto EM: AIDS related malignancies in Brazil. Curr Opin Oncol; 2007 Sep;19(5):476-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS related malignancies in Brazil.
  • PURPOSE OF REVIEW: There have been relatively few studies of HIV-related malignancies in Brazil.
  • Universal access to antiretroviral drugs in Brazil has changed both the mortality and morbidity rates of AIDS.
  • Nevertheless, there is also extreme poverty in both urban and rural areas and complications of prolonged immune suppression such as mycobacterial and malignant diseases have put a significant strain on the country's healthcare system.
  • This brief review outlines the existing data regarding AIDS related malignancies in the largest Latin American country.
  • In the studies done of HIV malignancies in Brazil, it appears that these tumors are histologically similar to those that occur in other equatorial countries and differ somewhat from those seen in Europe and the US.
  • SUMMARY: The existence of federally sponsored highly active antiretroviral therapy, clinicians and healthcare providers experienced in the care of HIV patients and high incidence of malignancies associated with oncogenic viruses make Brazil an important site for clinical and basic research in AIDS and immunodeficiency related malignancies.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AIDS. 2005 Oct;19 Suppl 4:S27-30 [16249650.001]
  • [Cites] East Afr Med J. 2005 Sep;82(9 Suppl):S133-4 [16619688.001]
  • [Cites] J Med Virol. 2006 Jun;78(6):719-23 [16628586.001]
  • [Cites] Braz J Med Biol Res. 2006 May;39(5):573-80 [16648893.001]
  • [Cites] Int J Hematol. 2006 Nov;84(4):337-42 [17118760.001]
  • [Cites] Pathol Res Pract. 2007;203(1):1-7 [17157997.001]
  • [Cites] J Infect Dis. 2000 May;181(5):1562-8 [10823754.001]
  • [Cites] AIDS. 2000 Dec 22;14(18):2929-36 [11153674.001]
  • [Cites] J Clin Microbiol. 2002 Sep;40(9):3341-5 [12202576.001]
  • [Cites] Int J Dermatol. 2004 Sep;43(9):643-7 [15357742.001]
  • [Cites] AIDS Patient Care STDS. 1998 Aug;12(8):619-23 [15468433.001]
  • [Cites] J Acquir Immune Defic Syndr. 1993 Aug;6(8):959-63 [8315579.001]
  • [Cites] Am J Clin Pathol. 1996 Feb;105(2):230-7 [8607450.001]
  • [Cites] Blood. 1996 Jun 15;87(12):5279-86 [8652843.001]
  • [Cites] Leukemia. 1997 May;11(5):743-6 [9180301.001]
  • [Cites] J Infect Dis. 1998 Nov;178(5):1488-91 [9780272.001]
  • [Cites] J Gen Virol. 2005 Sep;86(Pt 9):2433-7 [16099900.001]
  • [Cites] Int J Infect Dis. 2005 Sep;9(5):239-50 [16095940.001]
  • (PMID = 17762574.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA070058; United States / NCI NIH HHS / CA / CA109232-05; United States / NCI NIH HHS / CA / CA109232-03S1; United States / FIC NIH HHS / TW / D43 TW000017; United States / NCI NIH HHS / CA / R01 CA109232; United States / NCI NIH HHS / CA / R01 CA163217; United States / NIDCR NIH HHS / DE / R01 DE018304-02; United States / NCI NIH HHS / CA / R01 CA109232-04; United States / NCI NIH HHS / CA / CA109232-03; United States / NCI NIH HHS / CA / CA109232-01; United States / NIDCR NIH HHS / DE / DE018304-01; United States / NIDCR NIH HHS / DE / R01 DE018304; United States / NCI NIH HHS / CA / CA109232-02; United States / NCI NIH HHS / CA / R01 CA109232-05; United States / NCI NIH HHS / CA / R01 CA109232-02; United States / NIDCR NIH HHS / DE / R01 DE018304-01; United States / NCI NIH HHS / CA / CA70058; United States / NIDCR NIH HHS / DE / R01 DE018304-03; United States / NIDCR NIH HHS / DE / DE018304-02; United States / NCI NIH HHS / CA / R01 CA109232-01; United States / NCI NIH HHS / CA / R01 CA109232-03S1; United States / NCI NIH HHS / CA / R01 CA109232-03; United States / NIDCR NIH HHS / DE / DE018304-03; United States / NCI NIH HHS / CA / CA109232-04; United States / FIC NIH HHS / TW / 5D43 TW00017-18
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Number-of-references] 22
  • [Other-IDs] NLM/ NIHMS191349; NLM/ PMC2855639
  •  go-up   go-down


58. Crum-Cianflone N, Hullsiek KH, Satter E, Marconi V, Weintrob A, Ganesan A, Barthel RV, Fraser S, Agan BK: Cutaneous malignancies among HIV-infected persons. Arch Intern Med; 2009 Jun 22;169(12):1130-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous malignancies among HIV-infected persons.
  • BACKGROUND: As the life expectancy of persons infected with human immunodeficiency virus (HIV) increases, cancers have become an important cause of morbidity and mortality.
  • Although cutaneous cancers are the most common malignant neoplasms in the general population, little data exist among HIV-positive persons, especially regarding the impact of HIV-specific factors.
  • METHODS: We evaluated the incidence rates and factors associated with the development of cutaneous malignancies among HIV-infected persons by examining data that were prospectively collected from a large HIV study that included 4490 participants (1986-2006).
  • RESULTS: Six percent of HIV-infected persons (n = 254) developed a cutaneous malignancy during 33 760 person-years of follow-up (mean, 7.5 years).
  • Since the advent of highly active antiretroviral therapy (HAART), the incidence rates of cutaneous non-AIDS-defining cancers (NADCs), in particular basal cell carcinoma, have exceeded the rates of cutaneous AIDS-defining cancers such as Kaposi sarcoma.
  • Factors associated with the development of cutaneous NADCs in the multivariate models included increasing age (hazard ratio [HR], 2.1; 95% confidence interval [CI], 1.7-2.6) and race.
  • CONCLUSIONS: At present, the most common cutaneous malignancies among HIV-infected persons are NADCs.
  • Cutaneous NADCs do not appear to be significantly associated with immune function or HAART but rather are related to traditional factors such as aging and skin color.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J STD AIDS. 1999 Dec;10(12):795-802 [10639060.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] AIDS. 2001 Mar 30;15(5):629-33 [11317001.001]
  • [Cites] Clin Microbiol Rev. 2002 Apr;15(2):310-26 [11932235.001]
  • [Cites] Br J Dermatol. 2002 Apr;146 Suppl 61:1-6 [11966724.001]
  • [Cites] Arch Dermatol. 2002 Jun;138(6):758-63 [12056956.001]
  • [Cites] Arch Dermatol. 2002 Jun;138(6):765-70 [12056957.001]
  • [Cites] J Am Acad Dermatol. 2002 Jul;47(1):1-17; quiz 18-20 [12077575.001]
  • [Cites] N Engl J Med. 2003 Apr 24;348(17):1681-91 [12711744.001]
  • [Cites] J R Soc Med. 2003 May;96(5):238-9 [12724438.001]
  • [Cites] Dermatol Surg. 2004 Apr;30(4 Pt 2):595-7 [15061841.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 1981 Jul 3;30(25):305-8 [6789108.001]
  • [Cites] N Engl J Med. 1986 Jan 9;314(2):131-2 [2934633.001]
  • [Cites] J Am Acad Dermatol. 1989 Apr;20(4):587-91 [2715405.001]
  • [Cites] Arch Dermatol. 1992 May;128(5):623-7 [1575523.001]
  • [Cites] J Am Acad Dermatol. 1993 Sep;29(3):400-6 [8349856.001]
  • [Cites] J Am Acad Dermatol. 1993 Oct;29(4):539-44 [7691905.001]
  • [Cites] Mayo Clin Proc. 1995 Aug;70(8):766-72 [7630215.001]
  • [Cites] Arch Dermatol. 1997 May;133(5):577-83 [9158410.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] Transplant Proc. 1998 Sep;30(6):2859-60 [9745599.001]
  • [Cites] Br J Cancer. 1998 Oct;78(7):966-70 [9764592.001]
  • [Cites] J Acquir Immune Defic Syndr. 1999 Aug 1;21 Suppl 1:S34-41 [10430217.001]
  • [Cites] J Clin Pathol. 1999 Apr;52(4):249-53 [10474513.001]
  • [Cites] Drugs Today (Barc). 2005 Jan;41(1):37-53 [15753968.001]
  • [Cites] JAMA. 2005 Aug 10;294(6):681-90 [16091570.001]
  • [Cites] Cancer. 2005 Oct 1;104(7):1505-11 [16104038.001]
  • [Cites] JAMA. 2005 Sep 28;294(12):1476-80 [16189357.001]
  • [Cites] J Am Acad Dermatol. 2005 Dec;53(6):1067-71 [16310071.001]
  • [Cites] J Am Acad Dermatol. 2006 Feb;54(2):189-206; quiz 207-10 [16443048.001]
  • [Cites] Br J Dermatol. 2006 Mar;154(3):498-504 [16445782.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 15;98(6):389-95 [16537831.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] Dermatol Clin. 2006 Oct;24(4):521-30, vii [17010780.001]
  • [Cites] Br J Dermatol. 2006 Nov;155(5):1079-80 [17034550.001]
  • [Cites] Ann Intern Med. 2007 Jan 16;146(2):87-95 [17227932.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] J Infect Dis. 2007 Sep 15;196(6):876-83 [17703418.001]
  • [Cites] AIDS. 2007 Sep 12;21(14):1957-63 [17721103.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • (PMID = 19546414.001).
  • [ISSN] 1538-3679
  • [Journal-full-title] Archives of internal medicine
  • [ISO-abbreviation] Arch. Intern. Med.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / HU0001-05-2-0011; United States / PHS HHS / / HU0001-05-2-0011
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  • [Other-IDs] NLM/ NIHMS127594; NLM/ PMC2761839
  •  go-up   go-down


59. Smit C, Geskus R, Walker S, Sabin C, Coutinho R, Porter K, Prins M, CASCADE Collaboration: Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS; 2006 Mar 21;20(5):741-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Causes of death (COD) were categorized into three AIDS-related and seven non-AIDS-related causes.
  • Pre-HAART, AIDS opportunistic infections (OI) was the most common COD, followed by unknown and HIV/AIDS-unspecified.
  • In the HAART era, the cumulative incidence for all AIDS-related COD decreased, OI remaining the most important.
  • The cumulative risk of death from AIDS-related malignancies, OI and non-AIDS-related malignancies decreased significantly among homosexual men (MSM), whereas the risk of dying from (un)-intentional death increased significantly among injecting drug users (IDU).
  • A non-significant increase in hepatitis/liver-related death was seen in MSM, IDU and haemophiliacs.
  • OI remain the most common COD in the HAART era, suggesting that AIDS-related events will continue to be important in the future.
  • [MeSH-minor] AIDS-Related Opportunistic Infections / mortality. Adult. Antiretroviral Therapy, Highly Active. CD4 Lymphocyte Count. Cohort Studies. Disease Progression. Female. Follow-Up Studies. HIV Seropositivity. Hepatitis / mortality. Hepatitis / virology. Humans. Incidence. Lymphoma, AIDS-Related / mortality. Lymphoma, AIDS-Related / virology. Male. Multivariate Analysis. RNA, Viral / blood. Risk. Substance Abuse, Intravenous


60. Huebinger RM, Gomez R, McGee D, Chang LY, Bender JE, O'Keeffe T, Burris AM, Friese SM, Purdue GF, Hunt JL, Arnoldo BD, Horton JW, Barber RC: Association of mitochondrial allele 4216C with increased risk for sepsis-related organ dysfunction and shock after burn injury. Shock; 2010 Jan;33(1):19-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of mitochondrial allele 4216C with increased risk for sepsis-related organ dysfunction and shock after burn injury.
  • To remove confounding unrelated to burn injury, individuals were excluded if they presented with significant non-burn-related trauma (Injury Severity Score > or =16), traumatic or anoxic brain injury, spinal cord injury, were HIV/AIDS positive, had active malignancy, or survived less than 48 h postadmission.
  • Within this cohort of patients, carriage of the 4216C allele was significantly associated by unadjusted analysis with increased risk for sepsis-related organ dysfunction or septic shock (P = 0.011).
  • After adjustment for full-thickness burn size, inhalation injury, age, and sex, carriage of the 4216C allele was associated with complicated sepsis (adjusted odds ratio = 3.7; 95% confidence interval, 1.5-9.1; P = 0.005), relative to carriers of the T allele.

  • MedlinePlus Health Information. consumer health - Burns.
  • MedlinePlus Health Information. consumer health - Sepsis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19487983.001).
  • [ISSN] 1540-0514
  • [Journal-full-title] Shock (Augusta, Ga.)
  • [ISO-abbreviation] Shock
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / 5P50 GM21681-42; United States / NIGMS NIH HHS / GM / 5T32 GM00859313; United States / NIGMS NIH HHS / GM / R01-GM057054-09
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Mitochondrial; EC 1.6.99.3 / NADH Dehydrogenase; EC 1.6.99.3 / NADH dehydrogenase subunit 1, human
  •  go-up   go-down


61. Morton LM, Curtis RE, Linet MS, Bluhm EC, Tucker MA, Caporaso N, Ries LA, Fraumeni JF Jr: Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype. J Clin Oncol; 2010 Nov 20;28(33):4935-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype.
  • PURPOSE: Previous studies have shown increased risks of second malignancies after non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL); however, no earlier investigation has quantified differences in risk of new malignancy by lymphoma subtype.
  • PATIENTS AND METHODS: We evaluated second cancer and leukemia risks among 43,145 1-year survivors of CLL/small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL), or follicular lymphoma (FL) from 11 Surveillance, Epidemiology, and End Results (SEER) population-based registries during 1992 to 2006.
  • RESULTS: Among patients without HIV/AIDS-related lymphoma, lung cancer risks were significantly elevated after CLL/SLL and FL but not after DLBCL (standardized incidence ratio [SIR], CLL/SLL = 1.42, FL = 1.28, DLBCL = 1.00; Poisson regression P for difference among subtypes, P(Diff) = .001).
  • Patients with HIV/AIDS-related lymphoma (n = 932) were predominantly diagnosed with DLBCL and had significantly and substantially elevated risks for second anal cancer (SIR = 120.50) and Kaposi's sarcoma (SIR = 138.90).
  • CONCLUSION: Our findings suggest that differing immunologic alterations, treatments (eg, alkylating agent chemotherapy), genetic susceptibilities, and other risk factors (eg, viral infections, tobacco use) among lymphoma subtypes contribute to the patterns of second malignancy risk.
  • Elucidating these patterns may provide etiologic clues to lymphoma as well as to the second malignancies.

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):925-33 [15824165.001]
  • [Cites] Am J Epidemiol. 2010 Feb 1;171(3):267-76 [20047977.001]
  • [Cites] Br J Cancer. 2005 Jul 11;93(1):159-66 [15970927.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2402-6 [16214923.001]
  • [Cites] N Engl J Med. 2005 Nov 17;353(20):2135-47 [16291983.001]
  • [Cites] Lung Cancer. 2005 Dec;50(3):419-20 [16125820.001]
  • [Cites] J Clin Oncol. 2006 Apr 1;24(10):1568-74 [16520465.001]
  • [Cites] Cancer. 2006 Jul 1;107(1):108-15 [16708354.001]
  • [Cites] Haematologica. 2006 Nov;91(11):1481-8 [17043014.001]
  • [Cites] Leuk Lymphoma. 2006 Nov;47(11):2314-20 [17107903.001]
  • [Cites] AIDS. 2007 Jan 11;21(2):207-13 [17197812.001]
  • [Cites] Int J Cancer. 2007 Mar 1;120(5):1099-102 [17131330.001]
  • [Cites] Cancer Causes Control. 2007 Mar;18(2):135-42 [17235495.001]
  • [Cites] Int J Cancer. 2007 Jul 1;121(1):151-6 [17351903.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4617-26 [17311989.001]
  • [Cites] Blood. 2007 Jul 15;110(2):695-708 [17389762.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] Int J Cancer. 2008 Jan 1;122(1):144-54 [17708556.001]
  • [Cites] Cancer Causes Control. 2008 Feb;19(1):43-50 [17906957.001]
  • [Cites] Haematologica. 2008 Mar;93(3):398-404 [18268277.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Apr;6(4):451-8 [18387498.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4029-38 [18263783.001]
  • [Cites] J Clin Oncol. 2008 Apr 10;26(11):1850-7 [18347006.001]
  • [Cites] Expert Rev Anticancer Ther. 2008 Apr;8(4):605-15 [18402527.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] Expert Opin Pharmacother. 2008 Jun;9(9):1481-94 [18518779.001]
  • [Cites] Hematol Oncol Clin North Am. 2008 Oct;22(5):941-52, ix [18954744.001]
  • [Cites] Blood. 2008 Dec 15;112(13):5150-60 [18796628.001]
  • [Cites] Blood. 2009 Jan 29;113(5):1175-83 [18971419.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2454-60 [10561309.001]
  • [Cites] Cancer. 2001 Feb 15;91(4):874-80 [11241258.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1610-8 [11250989.001]
  • [Cites] J Natl Cancer Inst. 2002 Feb 6;94(3):182-92 [11830608.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1 Suppl 2):10-24 [11842384.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3878-84 [12228208.001]
  • [Cites] Br J Cancer. 2003 Jan 13;88(1):74-8 [12556962.001]
  • [Cites] Med Oncol. 2003;20(3):211-20 [14514970.001]
  • [Cites] Eur J Cancer. 2004 Feb;40(3):383-9 [14746857.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1222-8 [14576060.001]
  • [Cites] Cancer. 2004 May 1;100(9):1902-8 [15112271.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1083-91 [15247562.001]
  • [Cites] J Natl Cancer Inst. 1992 Sep 16;84(18):1422-7 [1512794.001]
  • [Cites] Eur J Haematol. 1994 Oct;53(4):218-22 [7957806.001]
  • [Cites] J Natl Cancer Inst. 1995 Apr 5;87(7):524-30 [7707439.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):565-71 [8636772.001]
  • [Cites] Int J Cancer. 1997 Nov 27;73(5):645-50 [9398040.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):216-28 [15578683.001]
  • [Cites] N Engl J Med. 2009 Feb 12;360(7):659-67 [19213679.001]
  • [Cites] J Natl Cancer Inst. 2009 Feb 18;101(4):248-55 [19211444.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):904-10 [19114699.001]
  • [Cites] Nat Genet. 2009 Aug;41(8):873-5 [19620980.001]
  • [Cites] J Natl Cancer Inst. 2009 Aug 19;101(16):1120-30 [19648510.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4573-5 [15741224.001]
  • (PMID = 20940199.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3020697
  •  go-up   go-down


62. Majerciak V, Yamanegi K, Allemand E, Kruhlak M, Krainer AR, Zheng ZM: Kaposi's sarcoma-associated herpesvirus ORF57 functions as a viral splicing factor and promotes expression of intron-containing viral lytic genes in spliceosome-mediated RNA splicing. J Virol; 2008 Mar;82(6):2792-801
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kaposi's sarcoma-associated herpesvirus ORF57 functions as a viral splicing factor and promotes expression of intron-containing viral lytic genes in spliceosome-mediated RNA splicing.
  • Kaposi's sarcoma-associated herpesvirus (KSHV) ORF57 facilitates the expression of both intronless viral ORF59 genes and intron-containing viral K8 and K8.1 genes (V.
  • In this study, we showed that disruption of ORF57 in a KSHV genome led to increased accumulation of ORF50 and K8 pre-mRNAs and reduced expression of ORF50 and K-bZIP proteins but had no effect on latency-associated nuclear antigen (LANA).
  • Although Epstein-Barr virus EB2, a closely related homolog of ORF57, had a similar activity in the cotransfection assays, herpes simplex virus type 1 ICP27 was inactive.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1996 May 16;334(20):1292-7 [8609946.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6641-6 [8692871.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14862-7 [8962146.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 24;93(26):15081-5 [8986767.001]
  • [Cites] J Virol. 1997 Jun;71(6):4187-92 [9151804.001]
  • [Cites] Genes Dev. 1998 Mar 15;12(6):868-79 [9512520.001]
  • [Cites] Hum Mol Genet. 1998 May;7(5):919-32 [9536098.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8852-7 [9671768.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10866-71 [9724796.001]
  • [Cites] Science. 2006 Jun 30;312(5782):1961-5 [16809543.001]
  • [Cites] Mol Cell. 2006 Jul 7;23(1):49-59 [16818232.001]
  • [Cites] J Virol. 2006 Oct;80(19):9720-9 [16973576.001]
  • [Cites] J Biol Chem. 2006 Sep 22;281(38):28365-78 [16829516.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 10;103(41):15190-5 [17005724.001]
  • [Cites] J Biol Chem. 2006 Dec 1;281(48):36510-7 [17028184.001]
  • [Cites] J Virol. 2006 Dec;80(24):11968-81 [17020939.001]
  • [Cites] J Virol. 2007 Feb;81(3):1062-71 [17108026.001]
  • [Cites] Virology. 2001 Sep 15;288(1):119-28 [11543664.001]
  • [Cites] EMBO J. 2001 Oct 15;20(20):5769-78 [11598019.001]
  • [Cites] Mol Cell Biol. 2001 Nov;21(22):7673-81 [11604503.001]
  • [Cites] Methods Mol Biol. 1999;118:309-14 [10549533.001]
  • [Cites] Methods Mol Biol. 1999;118:315-21 [10549534.001]
  • [Cites] J Virol. 2000 Jan;74(2):1038-44 [10623771.001]
  • [Cites] J Virol Methods. 2000 Mar;85(1-2):203-14 [10716353.001]
  • [Cites] J Virol. 2000 Apr;74(8):3586-97 [10729134.001]
  • [Cites] RNA. 2000 Sep;6(9):1197-211 [10999598.001]
  • [Cites] J Virol. 2000 Nov;74(21):10187-93 [11024147.001]
  • [Cites] J Virol. 2000 Dec;74(24):11977-82 [11090200.001]
  • [Cites] Genes Dev. 2000 Dec 15;14(24):3166-78 [11124808.001]
  • [Cites] J Virol. 2001 Feb;75(3):1487-506 [11152521.001]
  • [Cites] Nature. 2001 Jan 25;409(6819):539-42 [11206553.001]
  • [Cites] EMBO J. 2001 Jan 15;20(1-2):187-96 [11226169.001]
  • [Cites] J Virol. 2001 May;75(9):4376-85 [11287586.001]
  • [Cites] Blood. 2001 May 15;97(10):3244-50 [11342455.001]
  • [Cites] Curr Opin Cell Biol. 2001 Jun;13(3):302-9 [11343900.001]
  • [Cites] Biochem Soc Trans. 2001 May;29(Pt 2):15-26 [11356120.001]
  • [Cites] J Virol. 2001 Jul;75(13):6033-41 [11390605.001]
  • [Cites] J Virol. 2001 Aug;75(15):6786-99 [11435557.001]
  • [Cites] Virology. 2002 Mar 1;294(1):189-98 [11886277.001]
  • [Cites] J Biol Chem. 2002 Apr 26;277(17):14547-56 [11832484.001]
  • [Cites] J Virol. 2002 Jun;76(12):6213-23 [12021355.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10683-8 [12145325.001]
  • [Cites] J Virol. 2002 Dec;76(24):12877-89 [12438613.001]
  • [Cites] J Virol. 2003 Jan;77(2):1441-51 [12502859.001]
  • [Cites] Cancer Cell. 2003 Jan;3(1):1-3 [12559168.001]
  • [Cites] J Virol. 2003 Mar;77(6):3809-15 [12610155.001]
  • [Cites] J Virol. 2003 May;77(10):5578-88 [12719550.001]
  • [Cites] Rev Med Virol. 2003 May-Jun;13(3):173-84 [12740832.001]
  • [Cites] J Virol. 2003 Aug;77(16):8893-914 [12885907.001]
  • [Cites] J Virol. 2003 Sep;77(17):9590-612 [12915572.001]
  • [Cites] J Virol. 2003 Sep;77(17):9652-61 [12915577.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Aug;4(8):605-12 [12923522.001]
  • [Cites] J Biol Chem. 2003 Sep 26;278(39):37790-8 [12857728.001]
  • [Cites] J Virol. 1999 May;73(5):4181-7 [10196314.001]
  • [Cites] J Gen Virol. 1999 May;80 ( Pt 5):1311-6 [10355778.001]
  • [Cites] J Virol. 1999 Nov;73(11):9348-61 [10516043.001]
  • [Cites] Biochem J. 2005 Apr 15;387(Pt 2):295-308 [15537388.001]
  • [Cites] Blood. 2005 May 15;105(10):4028-34 [15687238.001]
  • [Cites] Biochem Soc Trans. 2005 Jun;33(Pt 3):443-6 [15916537.001]
  • [Cites] J Virol. 2005 Nov;79(22):14207-21 [16254356.001]
  • [Cites] J Virol. 2005 Dec;79(24):15099-106 [16306581.001]
  • [Cites] J Virol. 2006 Jun;80(11):5251-60 [16699005.001]
  • [Cites] J Virol. 2004 Jan;78(1):340-52 [14671116.001]
  • [Cites] Virology. 2004 Jan 20;318(2):542-55 [14972523.001]
  • [Cites] J Mol Biol. 2004 Apr 9;337(5):1091-108 [15046980.001]
  • [Cites] J Biomed Sci. 2004 May-Jun;11(3):278-94 [15067211.001]
  • [Cites] J Biol Chem. 2004 Jul 30;279(31):33001-11 [15155762.001]
  • [Cites] J Virol. 1994 Dec;68(12):7790-9 [7966568.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] J Biol Chem. 1995 Feb 10;270(6):2411-4 [7852296.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]
  • [Cites] J Virol. 1995 Nov;69(11):7187-95 [7474140.001]
  • [Cites] Nat Med. 1996 Mar;2(3):342-6 [8612236.001]
  • (PMID = 18184716.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA013106; United States / NCI NIH HHS / CA / CA13106; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic-Leucine Zipper Transcription Factors; 0 / DNA Primers; 0 / DNA, Complementary; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2258979
  •  go-up   go-down


63. Ma Q, Cavallin LE, Yan B, Zhu S, Duran EM, Wang H, Hale LP, Dong C, Cesarman E, Mesri EA, Goldschmidt-Clermont PJ: Antitumorigenesis of antioxidants in a transgenic Rac1 model of Kaposi's sarcoma. Proc Natl Acad Sci U S A; 2009 May 26;106(21):8683-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kaposi's sarcoma (KS) is the major AIDS-associated malignancy.
  • Here, we show that expression of a constitutively active Rac1 (RacCA) driven by the alpha-smooth muscle actin promoter in transgenic mice is sufficient to cause KS-like tumors through mechanisms involving ROS-driven proliferation, up-regulation of AKT signaling, and hypoxia-inducible factor 1-alpha-related angiogenesis.
  • RacCA-induced tumors expressed KS phenotypic markers; displayed remarkable transcriptome overlap with KS lesions; and were, like KS, associated with male gender.
  • Consistent with a pathogenic role in KS, immunohistochemical analysis revealed that Rac1 is overexpressed in KSHV(+) spindle cells of AIDS-KS biopsies.
  • Our results demonstrate the direct oncogenicity of Rac1 and ROS and their contribution to a KS-like malignant phenotype, further underscoring the carcinogenic potential of oxidative stress in the context of chronic infection and inflammation.
  • They define the RacCA transgenic mouse as a model suitable for studying the role of oxidative stress in the pathogenesis and therapy of KS, with relevance to other inflammation-related malignancies.


64. Wang J, Stebbing J, Bower M: HIV-associated Kaposi sarcoma and gender. Gend Med; 2007 Sep;4(3):266-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-associated Kaposi sarcoma and gender.
  • BACKGROUND: Cancer in individuals living with HIV and AIDS is a common source of morbidity and mortality, especially in the underdeveloped world.
  • As antiretrovirals are distributed with greater equity across the globe, individuals with HIV and AIDS are living longer and developing malignancies, as opposed to other opportunistic infections.
  • OBJECTIVE: This article reviews the gender differences in studies of AIDS-associated cancers, examining factors related to transmission, treatment, and outcome.
  • METHODS: MEDLINE, PubMed, Ovid, conference proceedings, and abstract books were searched from 1983 onward for English-language publications and data on gender differences related to AIDS-associated cancers.
  • The search terms used were women or gender, cancer or tumor or malignancy, lymphoma or Kaposi, and HIV or AIDS.
  • CONCLUSION: Immunosuppression-induced malignancies in women, Kaposi sarcoma in particular, are likely to represent a global issue in the future.
  • [MeSH-major] AIDS-Related Opportunistic Infections / epidemiology. Herpesvirus 8, Human / isolation & purification. Sarcoma, Kaposi / epidemiology


65. Omakobia E, Hossain J, Nash J, Uhuegbu C: A hot, swollen joint in a cirrhotic patient. BMJ Case Rep; 2010;2010
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Underlying risk factors, such as diabetes, malignancy, chronic renal failure, rheumatoid arthritis, hepatobiliary disease and AIDS, should be assessed.
  • We postulate that this case supports the notion that the patient's knee effusion seeded during a primary K pneumoniae bacteraemia of intestinal origin and related to liver cirrhosis.

  • MedlinePlus Health Information. consumer health - Infectious Arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Rheumatol. 1989 Dec;8(4):517-21 [2692949.001]
  • [Cites] J Hosp Infect. 1994 Aug;27(4):299-305 [7963472.001]
  • [Cites] J Clin Gastroenterol. 1998 Dec;27(4):364-6 [9855273.001]
  • [Cites] Clin Orthop Relat Res. 1990 Feb;(251):241-5 [2295180.001]
  • [Cites] Rheumatology (Oxford). 2006 Aug;45(8):1039-41 [16829534.001]
  • [Cites] Aliment Pharmacol Ther. 2001 Dec;15(12):1851-9 [11736714.001]
  • [Cites] Clin Infect Dis. 2003 Feb 1;36(3):319-27 [12539074.001]
  • [Cites] J Korean Med Sci. 2004 Aug;19(4):608-10 [15308857.001]
  • [Cites] Curr Opin Rheumatol. 2001 Jul;13(4):310-4 [11555734.001]
  • (PMID = 22798443.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Clavulanic Acids; 74469-00-4 / Amoxicillin-Potassium Clavulanate Combination; 86482-18-0 / ticarcillin-clavulanic acid; F93UJX4SWT / Ticarcillin
  • [Other-IDs] NLM/ PMC3030275
  •  go-up   go-down


66. Martin S, Elliott-DeSorbo DK, Wolters PL, Toledo-Tamula MA, Roby G, Zeichner S, Wood LV: Patient, caregiver and regimen characteristics associated with adherence to highly active antiretroviral therapy among HIV-infected children and adolescents. Pediatr Infect Dis J; 2007 Jan;26(1):61-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patient, caregiver and regimen characteristics associated with adherence to highly active antiretroviral therapy among HIV-infected children and adolescents.
  • Only 8% (n = 2) of child-caregiver pairs reported complete agreement regarding who held responsibility for medication-related tasks.
  • Adherence is related to surrogate markers of HIV disease but not to child or caregiver demographic variables.
  • Responsibilities for medication-related tasks should be clarified among family members, regimen knowledge should be emphasized and caregivers should avoid assigning treatment responsibility to a child prematurely.


67. Alizadeh AA, Bohen SP, Lossos C, Martinez-Climent JA, Ramos JC, Cubedo-Gil E, Harrington WJ Jr, Lossos IS: Expression profiles of adult T-cell leukemia-lymphoma and associations with clinical responses to zidovudine and interferon alpha. Leuk Lymphoma; 2010 Jul;51(7):1200-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adult T-cell leukemia-lymphoma (ATLL) is an HTLV-1-associated lymphoproliferative malignancy that is frequently fatal.
  • GEPs were also related to genetic aberrations determined by comparative genomic hybridization.
  • Demonstration of specific gene expression signatures associated with response to AZT-IFNalpha therapy may provide novel insights into the mechanisms of action in ATLL.

  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • Hazardous Substances Data Bank. ZIDOVUDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. ArrayExpress: Data: Microarray .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2010 Jul;51(7):1157-8 [20388057.001]
  • (PMID = 20370541.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / P30 AI073961; United States / NCI NIH HHS / CA / P30 CA124435; United States / NCI NIH HHS / CA / R01 CA109335; United States / NCI NIH HHS / CA / R01 CA109335; United States / NCI NIH HHS / CA / R01 CA122105
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Biomarkers, Tumor; 0 / Interferon-alpha; 0 / RNA, Messenger; 4B9XT59T7S / Zidovudine
  • [Other-IDs] NLM/ NIHMS636985; NLM/ PMC4296320
  •  go-up   go-down


68. Lim ST, Levine AM: Non-AIDS-defining cancers and HIV infection. Curr HIV/AIDS Rep; 2005 Aug;2(3):146-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-AIDS-defining cancers and HIV infection.
  • With fewer patients now succumbing to infectious complications of AIDS, other HIV-related morbidities, such as malignancies, have become increasingly important.
  • Apart from Kaposi's sarcoma, non-Hodgkin's lymphoma, and cervical cancer, which are considered as AIDS-defining, several additional cancers, referred to as non-AIDS-defining cancers, are also statistically increased in HIV-infected persons.
  • These include Hodgkin's disease, anal carcinoma, lung cancer, nonmelanomatous skin cancer, and testicular germ cell tumors, among others.
  • However, the types of cancer observed at an increased frequency and the relative risks reported vary widely among studies.
  • Although immunosuppression is consistently associated with an increased risk of AIDS-related malignancies, the role of immunosuppression in the pathogenesis of non-AIDS- defining cancers is controversial.
  • Although data regarding the optimal management of these cancers are lacking, current studies suggest that patients with HIV-associated malignancies should be treated with similar approaches to those of their counterparts in the general population.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):527-33 [12679705.001]
  • [Cites] Sex Transm Dis. 2004 Feb;31(2):96-9 [14743072.001]
  • [Cites] Eur J Epidemiol. 1995 Dec;11(6):609-14 [8861842.001]
  • [Cites] Ann Thorac Surg. 2003 Feb;75(2):367-71 [12607641.001]
  • [Cites] J Acquir Immune Defic Syndr. 2000 Aug 15;24(5):444-50 [11035615.001]
  • [Cites] Hematol Oncol Clin North Am. 1991 Apr;5(2):343-56 [2022598.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] J Natl Cancer Inst. 1997 Nov 5;89(21):1602-8 [9362158.001]
  • [Cites] AIDS. 2003 Feb 14;17(3):371-5 [12556691.001]
  • [Cites] AIDS Care. 1996 Feb;8(1):5-14 [8664369.001]
  • [Cites] Ann Oncol. 1993 Sep;4(8):635-41 [8240994.001]
  • [Cites] J Clin Oncol. 1995 Oct;13(10):2540-6 [7595705.001]
  • [Cites] Eur J Cancer. 2001 Jul;37(10):1276-87 [11423259.001]
  • [Cites] AIDS. 1998 Mar 26;12(5):495-503 [9543448.001]
  • [Cites] J Infect Dis. 1998 Feb;177(2):361-7 [9466522.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):314-9 [9525431.001]
  • [Cites] JAMA. 1999 May 19;281(19):1822-9 [10340370.001]
  • [Cites] J Clin Oncol. 1995 Nov;13(11):2705-11 [7595728.001]
  • [Cites] Cancer. 2001 Dec 1;92(11):2739-45 [11753946.001]
  • [Cites] Int J STD AIDS. 2001 Feb;12(2):100-2 [11236097.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1984-8 [12200356.001]
  • [Cites] Am J Med. 1985 Feb;78(2):211-5 [3918441.001]
  • [Cites] AIDS. 1999 May 7;13(7):839-43 [10357384.001]
  • [Cites] AIDS. 2001 Nov 9;15(16):2157-64 [11684935.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):978-85 [15220706.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] N Engl J Med. 1998 Mar 26;338(13):853-60 [9516219.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3447-53 [12972519.001]
  • [Cites] Cancer. 1992 Jul 15;70(2):432-6 [1617592.001]
  • [Cites] Cancer. 1990 May 15;65(10):2248-54 [2346909.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] Ann Oncol. 1999 Feb;10(2):189-95 [10093688.001]
  • [Cites] Cancer. 2000 Feb 1;88(3):563-9 [10649248.001]
  • [Cites] Ann Oncol. 2003 Oct;14(10):1562-9 [14504059.001]
  • [Cites] AIDS. 2002 May 24;16(8):1155-61 [12004274.001]
  • [Cites] Ann Intern Med. 2003 Mar 18;138(6):453-9 [12639077.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1391-7 [7538557.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1348-9; author reply 1349-50 [15051794.001]
  • [Cites] Clin Infect Dis. 2003 Jul 15;37(2):292-8 [12856222.001]
  • [Cites] Am J Med. 2000 Jun 1;108(8):634-41 [10856411.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4):480-8 [10950375.001]
  • [Cites] Hematol Oncol Clin North Am. 1996 Oct;10(5):997-1010 [8880192.001]
  • [Cites] Br J Cancer. 1998 Oct;78(7):966-70 [9764592.001]
  • [Cites] Chest. 1993 Feb;103(2):410-3 [8432128.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Sep;11(9):1587-93 [3928544.001]
  • [Cites] Blood. 1999 Apr 1;93(7):2319-26 [10090942.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12667-71 [11058153.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1101-5 [9169819.001]
  • [Cites] Chest. 1998 Jan;113(1):154-61 [9440583.001]
  • [Cites] Mutat Res. 1999 Oct 19;429(2):249-59 [10526209.001]
  • [Cites] Eur J Cancer. 2000 Apr;36(6):754-8 [10762748.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10):1922-7 [12743144.001]
  • [Cites] Fundam Appl Toxicol. 1996 Aug;32(2):148-58 [8921318.001]
  • [Cites] Mutagenesis. 2000 Sep;15(5):405-10 [10970446.001]
  • [Cites] Int J Cancer. 2001 Dec 1;94(5):753-7 [11745473.001]
  • [Cites] J Acquir Immune Defic Syndr. 2001 Dec 15;28(5):422-8 [11744829.001]
  • [Cites] Ann Oncol. 1991 Feb;2 Suppl 2:201-5 [1710920.001]
  • [Cites] Lung Cancer. 2002 Apr;36(1):9-14 [11891027.001]
  • [Cites] Br J Cancer. 2003 Aug 4;89(3):457-9 [12888811.001]
  • [Cites] Am J Surg Pathol. 1996 Dec;20(12):1520-4 [8944046.001]
  • [Cites] Chest. 1992 Dec;102(6):1704-8 [1446476.001]
  • (PMID = 16091262.001).
  • [ISSN] 1548-3568
  • [Journal-full-title] Current HIV/AIDS reports
  • [ISO-abbreviation] Curr HIV/AIDS Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 64
  •  go-up   go-down


69. Orem J, Otieno MW, Banura C, Katongole-Mbidde E, Johnson JL, Ayers L, Ghannoum M, Fu P, Feigal EG, Black J, Whalen C, Lederman M, Remick SC: Capacity building for the clinical investigation of AIDS malignancy in East Africa. Cancer Detect Prev; 2005;29(2):133-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Capacity building for the clinical investigation of AIDS malignancy in East Africa.
  • PURPOSE: To build capacity in the resource-poor setting to support the clinical investigation and treatment of AIDS-related malignancies in a region of the world hardest hit by the AIDS pandemic.
  • METHODS: An initial MEDLINE database search for international collaborative partnerships dedicated to AIDS malignancies in developing countries failed to identify any leads.
  • Building on the formal Uganda-Case Western Reserve University (Case) Research Collaboration dating back to 1987, established NIH-supported centers of research excellence at Case, and expanding activities in Kenya, scientific and training initiatives, research capital amongst our institutions are emerging to sustain a international research enterprise focused on AIDS and other viral-related malignancies.
  • An oral chemotherapy feasibility trial in AIDS lymphoma is near completion; a second lymphoma trial of byrostatin and vincristine is anticipated and a feasibility trial of indinavir for endemic Kaposi's sarcoma is planned.
  • CONCLUSIONS: In the absence of published reports of evolving international partnerships dedicated to AIDS malignancy in resource constrained settings, we feel it important for such progress on similar or related international collaborative pursuits to be published.


70. Nunes Mde G, Azevedo-e-Silva M, Gonçalves CP, Trope BM, Oliveira Ldo H, Ramos-e-Silva M: Human papillomavirus detection and typification in cutaneous and mucosal lesions of HIV-seropositive patients. Int J STD AIDS; 2008 Sep;19(9):611-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • High-risk human papillomavirus (HPV) in a lesion is related to an increased chance of neoplasic transformation, especially when with immunosuppression, as in HIV infection.
  • The frequency of malignancy, its association with the HPV type detected and some clinical variables were also assessed.
  • Of the lesions, 36.8% were already premalignant or malignant, and the frequency of moderate or severe dysplasia was higher in the study patients than that described in the HIV-seronegative population.
  • There was no significant association between the clinical variables and an increase in the prevalence of premalignant or malignant lesions.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Warts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18725552.001).
  • [ISSN] 0956-4624
  • [Journal-full-title] International journal of STD & AIDS
  • [ISO-abbreviation] Int J STD AIDS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


71. Amara S, Dezube BJ, Cooley TP, Pantanowitz L, Aboulafia DM: HIV-associated monoclonal gammopathy: a retrospective analysis of 25 patients. Clin Infect Dis; 2006 Nov 1;43(9):1198-205
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-associated monoclonal gammopathy: a retrospective analysis of 25 patients.
  • We sought to describe the laboratory findings and clinical course of MGUS, including association with plasma cell disorders, other malignancies, and infections, in 25 HIV-infected patients with a detectable serum monoclonal protein.
  • After a mean follow-up duration of 21 months, 7 patients (28%) received a diagnosis of a malignancy (multiple myeloma, in 1 patient; non-Hodgkin lymphoma, in 1; Hodgkin lymphoma, in 1; Kaposi sarcoma, in 2; and plasmacytoma, in 2).
  • [MeSH-minor] Adult. Aged. Antiretroviral Therapy, Highly Active / adverse effects. Female. Hepatitis B / complications. Hepatitis C / complications. Humans. Lymphoma, AIDS-Related / complications. Male. Middle Aged. Retrospective Studies. Sarcoma, Kaposi / complications


72. Neuman HB, Charlson ME, Temple LK: Is there a role for decision aids in cancer-related decisions? Crit Rev Oncol Hematol; 2007 Jun;62(3):240-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is there a role for decision aids in cancer-related decisions?
  • Cancer-related decisions are challenging, requiring patients to evaluate associated medical and psychological outcomes within the context of their personal values.
  • Clinical decision aids are decisional support tools designed to facilitate patient-driven decision-making by providing relevant information on the options while eliciting and incorporating patient preferences; they have been designed to support decision-making in the prevention, screening, and treatment of cancer.
  • In randomized controlled trials, cancer-related decision aids have been shown to increase patients' knowledge regarding their disease, and may facilitate patients playing a more active role in decision-making.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17317206.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ireland
  • [Number-of-references] 93
  •  go-up   go-down


73. Uldrick TS, Wang V, O'Mahony D, Aleman K, Wyvill KM, Marshall V, Steinberg SM, Pittaluga S, Maric I, Whitby D, Tosato G, Little RF, Yarchoan R: An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without Multicentric Castleman disease. Clin Infect Dis; 2010 Aug 1;51(3):350-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without Multicentric Castleman disease.
  • BACKGROUND: Kaposi sarcoma-associated herpesvirus (KSHV) is the causal agent for Kaposi sarcoma (KS) and multicentric Castleman disease (MCD) in human immunodeficiency virus (HIV)-infected patients.
  • Patients with KSHV-MCD develop fevers, wasting, hypoalbuminemia, cytopenias, and hyponatremia that are related to overproduction of KSHV-encoded viral interleukin (IL)-6 (vIL-6) and human IL-6 (hIL-6).
  • CONCLUSIONS: A subset of patients with HIV and KSHV co-infection, but without MCD, can develop severe systemic inflammatory symptoms associated with elevated levels of KSHV vIL-6, IL-6, and KSHV viral loads.
  • Excess lytic activation of KSHV, production of the lytic gene product vIL6, and associated immunologic dysregulation may underlie the pathophysiology of these symptoms.
  • This IL-6-related inflammatory syndrome is important to consider in critically ill patients with HIV and KSHV co-infection.


74. Lin L, Lee JY, Kaplan LD, Dezube BJ, Noy A, Krown SE, Levine AM, Yu Y, Hayward GS, Ambinder RF: Effects of chemotherapy in AIDS-associated non-Hodgkin's lymphoma on Kaposi's sarcoma herpesvirus DNA in blood. J Clin Oncol; 2009 May 20;27(15):2496-502
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of chemotherapy in AIDS-associated non-Hodgkin's lymphoma on Kaposi's sarcoma herpesvirus DNA in blood.
  • PURPOSE: To determine the relative frequency with which Kaposi's sarcoma-associated herpesvirus/HHV-8 (KSHV) DNA is detected in peripheral-blood mononuclear cells (PBMCs) and in plasma of patients with AIDS-KS and AIDS-associated non-Hodgkin's lymphoma (NHL; AIDS-NHL); to determine whether the presence of viral DNA in plasma reflects lysis of tumor cells or reflects the presence of viremia (ie, virion-encapsidated DNA); and to determine the effect of lymphoma therapy on KSHV DNA.
  • PATIENTS AND METHODS: Samples were obtained from patients enrolled in AIDS Malignancy Consortium clinical trials and from healthy donors.
  • RESULTS: In patients with AIDS-KS, KSHV DNA was detected in PBMC (54%) and in plasma (62%).
  • In patients with AIDS-NHL, KSHV DNA was detected in PBMC (19%) and in plasma (22%).
  • In six patients with AIDS-NHL who were treated with chemotherapy (with or without rituximab), KSHV copy number declined in PBMC and in plasma.
  • CONCLUSION: KSHV DNA is sometimes detected in PBMC or in plasma of patients with AIDS-NHL without KS.
  • Among patients with KSHV DNA detected in PBMC or in plasma, copy number does not distinguish between patients with AIDS-NHL and AIDS-KS.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2000 Nov;74(21):10187-93 [11024147.001]
  • [Cites] AIDS. 2007 Jul 31;21(12):1541-5 [17630548.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4055-63 [11110673.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1659-65 [11245480.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):153-9 [11773164.001]
  • [Cites] J Virol. 2002 Apr;76(7):3421-39 [11884567.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1186-93 [12142371.001]
  • [Cites] J Natl Cancer Inst. 2002 Nov 6;94(21):1614-9 [12419787.001]
  • [Cites] J Infect Dis. 2003 Jan 1;187(1):149-53 [12508160.001]
  • [Cites] Clin Infect Dis. 2003 May 1;36(9):1144-51 [12715309.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3350-6 [17664482.001]
  • [Cites] J Infect Dis. 2007 Oct 15;196(8):1163-6 [17955434.001]
  • [Cites] Blood. 2007 Dec 1;110(12):4132-3 [18024800.001]
  • [Cites] Ann Intern Med. 2007 Dec 18;147(12):836-9 [18087054.001]
  • [Cites] Blood. 2008 Apr 15;111(8):3986-90 [18172004.001]
  • [Cites] Cancer Lett. 2008 May 18;263(2):182-8 [18234418.001]
  • [Cites] J Infect Dis. 2008 Jul 1;198(1):23-30 [18491970.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2028-32 [12727814.001]
  • [Cites] AIDS. 2004 Feb 20;18(3):485-93 [15090801.001]
  • [Cites] Diagn Mol Pathol. 2004 Jun;13(2):61-8 [15167006.001]
  • [Cites] Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6189-93 [15448006.001]
  • [Cites] Lancet. 1995 Sep 23;346(8978):799-802 [7674745.001]
  • [Cites] Nat Med. 1995 Dec;1(12):1274-8 [7489408.001]
  • [Cites] Am J Pathol. 1996 Jun;148(6):1741-8 [8669460.001]
  • [Cites] Blood. 1996 Jul 1;88(1):297-301 [8704186.001]
  • [Cites] J Infect Dis. 1996 Nov;174(5):1101-5 [8896516.001]
  • [Cites] AIDS. 1997 Apr;11(5):F35-45 [9108935.001]
  • [Cites] J Virol. 1997 Oct;71(10):7963-8 [9311888.001]
  • [Cites] J Infect Dis. 1999 Sep;180(3):824-8 [10438372.001]
  • [Cites] J Infect Dis. 2005 Feb 1;191(3):367-71 [15633095.001]
  • [Cites] J Clin Oncol. 2005 Feb 10;23(5):990-8 [15598977.001]
  • [Cites] J Am Acad Dermatol. 2005 Jul;53(1):155-7 [15965441.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1538-43 [15914552.001]
  • [Cites] J Acquir Immune Defic Syndr. 2006 Feb 1;41(2):149-53 [16394845.001]
  • [Cites] Ann Hematol. 2006 Mar;85(3):185-7 [16341862.001]
  • [Cites] Int J Cancer. 2006 Dec 1;119(11):2673-6 [16991120.001]
  • [Cites] J Clin Oncol. 2006 Dec 1;24(34):5414-8 [17135642.001]
  • [Cites] N Engl J Med. 2000 Nov 9;343(19):1411-3 [11070109.001]
  • (PMID = 19349542.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA070058; United States / NCI NIH HHS / CA / P50 CA96888; United States / NCI NIH HHS / CA / U01 CA070047; United States / NCI NIH HHS / CA / U01 CA070019; United States / NCI NIH HHS / CA / U01 CA083038; United States / NCI NIH HHS / CA / U01 CA083035; United States / NCI NIH HHS / CA / U01 CA070072; United States / NCI NIH HHS / CA / U01 CA083118; United States / NCI NIH HHS / CA / U01 CA070081; United States / NCI NIH HHS / CA / U01 CA071375; United States / NCI NIH HHS / CA / U01 CA070079; United States / NCI NIH HHS / CA / U01 CA070054; United States / NCI NIH HHS / CA / U01 CA70081; United States / NCI NIH HHS / CA / U01 CA070062; United States / NCI NIH HHS / CA / U01 CA70058; United States / NCI NIH HHS / CA / U01 CA121947; United States / NCI NIH HHS / CA / U01 CA070080; United States / NCI NIH HHS / CA / P50 CA096888
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA, Viral
  • [Other-IDs] NLM/ PMC2684854
  •  go-up   go-down


75. Marin B, Thiébaut R, Bucher HC, Rondeau V, Costagliola D, Dorrucci M, Hamouda O, Prins M, Walker S, Porter K, Sabin C, Chêne G: Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS; 2009 Aug 24;23(13):1743-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy.
  • OBJECTIVE: To assess whether immunodeficiency is associated with the most frequent non-AIDS-defining causes of death in the era of combination antiretroviral therapy (cART).
  • RESULTS: Among 9858 patients (71 230 person-years follow-up), 597 died, 333 (55.7%) from non-AIDS-defining causes.
  • Non-AIDS-defining infection, liver disease, non-AIDS-defining malignancy and cardiovascular disease accounted for 53% of non-AIDS deaths.
  • For each 100 cells/microl increment in the latest CD4 cell count, we found a 64% (95% confidence interval 58-69%) reduction in risk of death from AIDS-defining causes and significant reductions in death from non-AIDS infections (32, 18-44%), end-stage liver disease (33, 18-46%) and non-AIDS malignancies (34, 21-45%).
  • Non-AIDS-defining causes of death were also associated with nadir CD4 while being cART-naive or duration of exposure to immunosuppression.
  • No relationship between risk of death from cardiovascular disease and CD4 cell count was found though there was a raised risk associated with elevated HIV RNA.
  • CONCLUSION: In the cART era, the most frequent non-AIDS-defining causes of death are associated with immunodeficiency, only cardiovascular disease was associated with high viral replication.
  • [MeSH-minor] AIDS-Related Opportunistic Infections / immunology. AIDS-Related Opportunistic Infections / mortality. Adolescent. Adult. Aged. Antiretroviral Therapy, Highly Active. CD4 Lymphocyte Count. Cardiovascular Diseases / complications. Cardiovascular Diseases / immunology. Cardiovascular Diseases / mortality. Epidemiologic Methods. Female. Humans. Immune Tolerance. Liver Diseases / complications. Liver Diseases / immunology. Liver Diseases / mortality. Male. Middle Aged. Neoplasms / complications. Neoplasms / immunology. Neoplasms / mortality. Young Adult


76. Kalpidis CD, Lysitsa SN, Lombardi T, Kolokotronis AE, Antoniades DZ, Samson J: Gingival involvement in a case series of patients with acquired immunodeficiency syndrome-related Kaposi sarcoma. J Periodontol; 2006 Mar;77(3):523-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gingival involvement in a case series of patients with acquired immunodeficiency syndrome-related Kaposi sarcoma.
  • BACKGROUND: This case series presents the polymorphic clinical characteristics of gingival acquired immunodeficieny syndrome (AIDS)-related Kaposi sarcoma (KS), a malignancy that is gradually becoming uncommon in developed nations.
  • An up-to-date overview of the related epidemiology, etiopathogenesis, histopathology, and treatment is provided, along with a pictorial guide to ease clinical diagnosis.
  • Thirty-two cases diagnosed with oral AIDS-related KS were retrieved between 1991 and 2004.
  • [MeSH-major] AIDS-Related Opportunistic Infections / pathology. Gingival Neoplasms / pathology. Sarcoma, Kaposi / pathology

  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16512768.001).
  • [ISSN] 0022-3492
  • [Journal-full-title] Journal of periodontology
  • [ISO-abbreviation] J. Periodontol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Nguyen ML, Farrell KJ, Gunthel CJ: Non-AIDS-Defining Malignancies in Patients with HIV in the HAART Era. Curr Infect Dis Rep; 2010 Jan;12(1):46-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-AIDS-Defining Malignancies in Patients with HIV in the HAART Era.
  • The introduction of highly active antiretroviral therapy (HAART) has drastically changed the scope and spectrum of diseases associated with HIV, shifting from AIDS-related to non-AIDS-related diseases.
  • Studies linking HIV/AIDS databases to cancer registries have shown a dramatic decrease in AIDS-related malignancies and a steady increase in non-AIDS-defining malignancies (NADM).
  • Meta-analysis of published studies show an increase in NADM over the general population, mostly among infection-related cancers such as anal cancer, Hodgkin lymphoma, and liver cancer.
  • Among the non-infection-related cancers, lung and skin cancers predominate.
  • As HIV-infected individuals survive longer, better screening strategies are needed to detect cancer earlier, and prospective data are needed to assess the impact of HAART on cancer outcomes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):527-33 [12679705.001]
  • [Cites] Immun Ageing. 2008 Sep 24;5:11 [18816370.001]
  • [Cites] Arch Intern Med. 2009 Jun 22;169(12):1130-8 [19546414.001]
  • [Cites] Curr Opin HIV AIDS. 2009 Jan;4(1):3-10 [19339934.001]
  • [Cites] Curr Opin Infect Dis. 2009 Feb;22(1):7-10 [19532075.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] Transplant Proc. 2008 Jul-Aug;40(6):1965-71 [18675102.001]
  • [Cites] AIDS. 2009 May 15;23(8):875-85 [19349851.001]
  • [Cites] AIDS. 2008 Oct 18;22(16):2135-41 [18832877.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Jul 1;36(3):861-8 [15213571.001]
  • [Cites] AIDS. 2004 Nov 19;18(17):2285-93 [15577541.001]
  • [Cites] Clin Infect Dis. 2009 Oct 1;49(7):1109-16 [19705973.001]
  • [Cites] AIDS. 2008 Apr 23;22(7):841-8 [18427202.001]
  • [Cites] J Acquir Immune Defic Syndr. 2006 Sep;43(1):47-55 [16936558.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1563-5 [15577408.001]
  • [Cites] Cancer. 2005 Oct 1;104(7):1505-11 [16104038.001]
  • [Cites] Obstet Gynecol Clin North Am. 2009 Mar;36(1):187-200 [19344856.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1984-8 [12200356.001]
  • [Cites] AIDS. 2005 Sep 2;19(13):1407-14 [16103772.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):884-90 [19114688.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):305-9 [19412116.001]
  • [Cites] AIDS. 2003 Jan 3;17(1):81-7 [12478072.001]
  • [Cites] Exp Gerontol. 2007 May;42(5):432-7 [17307327.001]
  • [Cites] J Natl Cancer Inst. 2009 Aug 19;101(16):1120-30 [19648510.001]
  • [Cites] AIDS Educ Prev. 2009 Jun;21(3 Suppl):3-13 [19537950.001]
  • [Cites] Dis Colon Rectum. 2001 Apr;44(4):506-12 [11330577.001]
  • [Cites] Lancet Oncol. 2009 Apr;10(4):321-2 [19350698.001]
  • [Cites] AIDS. 2009 Nov 13;23(17):2337-45 [19741479.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):6-7 [17617251.001]
  • [Cites] Int J Cancer. 2008 Jun 1;122(11):2590-3 [18224690.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] Dis Colon Rectum. 2008 Jun;51(6):829-35; discussion 835-7 [18363070.001]
  • [Cites] Am J Epidemiol. 2007 May 15;165(10):1143-53 [17344204.001]
  • [Cites] AIDS. 2007 Sep 12;21(14):1957-63 [17721103.001]
  • [Cites] AIDS. 2009 Jan 2;23(1):41-50 [19050385.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] Clin Infect Dis. 2007 Jul 1;45(1):103-10 [17554710.001]
  • [Cites] Hum Pathol. 2007 Sep;38(9):1293-304 [17707260.001]
  • [Cites] Oncol Rep. 2007 May;17(5):1121-6 [17390054.001]
  • [Cites] Arch Intern Med. 2008 Nov 24;168(21):2326-32; discussion 2332 [19029496.001]
  • [Cites] Lung Cancer. 2006 Jan;51(1):1-11 [16300854.001]
  • [Cites] Curr Infect Dis Rep. 2009 Sep;11(5):407-13 [19698285.001]
  • [Cites] J Hepatol. 2007 Oct;47(4):527-37 [17692986.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] Leuk Lymphoma. 2007 Oct;48(10):2058-9 [17917974.001]
  • [Cites] Lung Cancer. 2009 Sep;65(3):345-50 [19135758.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1383-8 [16549832.001]
  • (PMID = 21308498.001).
  • [ISSN] 1534-3146
  • [Journal-full-title] Current infectious disease reports
  • [ISO-abbreviation] Curr Infect Dis Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Abu Seadah AA, El Shikh ME: RAPD typing of Aspergillus chevalieri, Aspergillus nidulans, Aspergillus tetrazonus (quadrilineatus) and their teleomorphs using 5'-d[AACGCGCAAC]-3' and 5'-d[CCCGTCAGCA]-3' primers. Mol Biol Rep; 2008 Jun;35(2):89-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Moreover, mating-virulence correlation and the growing worry of opportunistic fungal infections in immunocompromised states associated with AIDS, cancer chemotherapy and organ transplantation protocols have been critically addressed nowadays.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Mol Evol. 1993 Aug;37(2):137-53 [8411203.001]
  • [Cites] Fungal Genet Biol. 2002 Oct;37(1):109-19 [12223195.001]
  • [Cites] Plant Physiol. 1993 Feb;101(2):349-52 [8278503.001]
  • [Cites] Clin Microbiol Rev. 1999 Jan;12(1):126-46 [9880478.001]
  • [Cites] Fungal Genet Biol. 1998 Aug;24(3):285-97 [9756710.001]
  • [Cites] Can J Microbiol. 1999 May;45(5):408-12 [10446716.001]
  • [Cites] J Hosp Infect. 1995 Jun;30 Suppl:339-51 [7560970.001]
  • [Cites] Nucleic Acids Res. 1990 Nov 25;18(22):6531-5 [1979162.001]
  • [Cites] Trans N Y Acad Sci. 1956 Feb;18(4):388-97 [13312068.001]
  • [Cites] Toxicol Lett. 1983 Dec;19(3):321-5 [6229060.001]
  • [Cites] J Clin Microbiol. 1995 Jun;33(6):1596-601 [7650194.001]
  • [Cites] J Mol Evol. 1971;1(1):1-17 [5173649.001]
  • [Cites] Science. 2000 May 19;288(5469):1185-6 [10841738.001]
  • [Cites] Medicine (Baltimore). 1998 Sep;77(5):345-54 [9772923.001]
  • [Cites] Mycopathologia. 1994 Nov;128(2):75-9 [7777037.001]
  • [Cites] Mol Plant Microbe Interact. 2003 May;16(5):398-404 [12744510.001]
  • [Cites] Trans N Y Acad Sci. 1955 Jun;17(8):627-35 [14396925.001]
  • [Cites] J Clin Microbiol. 1992 Dec;30(12):3290-3 [1452721.001]
  • [Cites] Nature. 1968 Feb 17;217(5129):624-6 [5637732.001]
  • [Cites] Mycoses. 1994 Jul-Aug;37(7-8):271-4 [7739658.001]
  • [Cites] Methods Enzymol. 1993;218:704-40 [8510556.001]
  • [Cites] Annu Rev Phytopathol. 1996;34:457-77 [15012552.001]
  • (PMID = 17268891.001).
  • [ISSN] 0301-4851
  • [Journal-full-title] Molecular biology reports
  • [ISO-abbreviation] Mol. Biol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA Primers
  •  go-up   go-down


79. Richard V, Nadella MV, Green PL, Lairmore MD, Feuer G, Foley JG, Rosol TJ: Transcriptional regulation of parathyroid hormone-related protein promoter P3 by ETS-1 in adult T-cell leukemia/lymphoma. Leukemia; 2005 Jul;19(7):1175-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcriptional regulation of parathyroid hormone-related protein promoter P3 by ETS-1 in adult T-cell leukemia/lymphoma.
  • Parathyroid hormone-related protein (PTHrP) plays a primary role in the development of humoral hypercalcemia of malignancy seen in the majority of adult T-cell leukemia/lymphoma (ATLL) patients with human T-cell lymphotropic virus type-1 (HTLV-1) infection.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Apr 1;93(7):2360-8 [10090947.001]
  • [Cites] Endocrinology. 2000 May;141(5):1882-92 [10803599.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3915-21 [10845928.001]
  • [Cites] AIDS Res Hum Retroviruses. 2000 Nov 1;16(16):1583-90 [11080795.001]
  • [Cites] Am J Pathol. 2001 Jun;158(6):2219-28 [11395400.001]
  • [Cites] Rev Endocr Metab Disord. 2000 Nov;1(4):253-63 [11706739.001]
  • [Cites] J Biol Chem. 2001 Dec 7;276(49):46661-70 [11590145.001]
  • [Cites] Gene. 2003 Jan 16;303:11-34 [12559563.001]
  • [Cites] Int J Oncol. 2003 Apr;22(4):799-805 [12632071.001]
  • [Cites] Mol Cell Endocrinol. 2003 Jun 30;204(1-2):155-68 [12850290.001]
  • [Cites] Clin Chem. 2003 Aug;49(8):1398-402 [12881458.001]
  • [Cites] Biochem J. 2003 Jun 15;372(Pt 3):787-97 [12628005.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 [6261256.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Oct;81(19):6207-11 [6091140.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):556-63 [3043221.001]
  • [Cites] Science. 1988 Sep 23;241(4873):1652-5 [2843985.001]
  • [Cites] Gene. 1989 Apr 15;77(1):95-105 [2744490.001]
  • [Cites] J Immunol. 1989 Aug 15;143(4):1283-9 [2545785.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Jul;86(14):5620-4 [2787512.001]
  • [Cites] J Endocrinol. 1989 Jul;122(1):219-27 [2788697.001]
  • [Cites] Biochem Biophys Res Commun. 1990 Mar 30;167(3):1134-8 [2322262.001]
  • [Cites] J Virol. 1990 Jun;64(6):2825-32 [2335818.001]
  • [Cites] J Exp Med. 1990 Sep 1;172(3):759-65 [2388034.001]
  • [Cites] Mol Endocrinol. 1990 Jun;4(6):851-8 [2233743.001]
  • [Cites] J Biol Chem. 1992 Jul 5;267(19):13623-8 [1618864.001]
  • [Cites] Mol Endocrinol. 1992 Oct;6(10):1642-52 [1280327.001]
  • [Cites] Curr Top Microbiol Immunol. 1992;182:421-4 [1490380.001]
  • [Cites] Blood. 1993 Feb 15;81(4):1017-24 [8427983.001]
  • [Cites] Cancer. 1993 May 1;71(9):2803-6 [8467460.001]
  • [Cites] Mol Endocrinol. 1993 Feb;7(2):273-82 [8469240.001]
  • [Cites] Endocrinology. 1993 Jun;132(6):2551-6 [8099324.001]
  • [Cites] Cancer Res. 1993 Jul 1;53(13):2980-6 [8319205.001]
  • [Cites] Blood. 1993 Aug 1;82(3):722-31 [8338942.001]
  • [Cites] J Biol Chem. 1993 Aug 5;268(22):16730-6 [8393873.001]
  • [Cites] J Virol. 1993 Oct;67(10):6087-95 [8371355.001]
  • [Cites] Urology. 1994 May;43(5):675-9 [8165768.001]
  • [Cites] J Bone Miner Res. 1994 May;9(5):639-44 [8053392.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):8960-3 [8090753.001]
  • [Cites] Endocrinology. 1995 Apr;136(4):1782-9 [7895691.001]
  • [Cites] Mol Cell Biol. 1995 Aug;15(8):4064-75 [7623802.001]
  • [Cites] Blood. 1995 Sep 15;86(6):2257-67 [7662973.001]
  • [Cites] Br J Cancer. 1995 Sep;72(3):702-7 [7669584.001]
  • [Cites] Mol Cell Endocrinol. 1995 Jun;111(2):225-32 [7556886.001]
  • [Cites] Endocrinology. 1995 Dec;136(12):5416-22 [7588290.001]
  • [Cites] J Cell Physiol. 1996 Jan;166(1):1-11 [8557757.001]
  • [Cites] Endocrinology. 1996 Apr;137(4):1349-57 [8625910.001]
  • [Cites] EMBO J. 1996 Jul 15;15(14):3744-50 [8670878.001]
  • [Cites] J Biol Chem. 1997 Feb 21;272(8):4953-8 [9030555.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13897-902 [9391124.001]
  • [Cites] J Biol Chem. 1998 May 8;273(19):11463-71 [9565558.001]
  • [Cites] J Biol Chem. 1998 Jun 5;273(23):14119-29 [9603911.001]
  • [Cites] Cancer Res. 1999 Dec 1;59(23):6015-22 [10606251.001]
  • [Cites] Mol Cell Endocrinol. 1999 Oct 25;156(1-2):13-23 [10612419.001]
  • (PMID = 15889157.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA077911; United States / NCI NIH HHS / CA / P01 CA100730-069003; United States / NCRR NIH HHS / RR / RR00168; United States / NCI NIH HHS / CA / CA100730; United States / NCRR NIH HHS / RR / P51 RR000168; United States / NCRR NIH HHS / RR / K26 RR000168; United States / NCI NIH HHS / CA / CA77911; United States / NCI NIH HHS / CA / P01 CA100730-03; None / None / / P01 CA100730-01; United States / NCI NIH HHS / CA / CA100730-03; United States / NCI NIH HHS / CA / P01 CA100730-01; United States / NCI NIH HHS / CA / CA100730-069003; United States / NCI NIH HHS / CA / P01 CA100730
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ETS1 protein, human; 0 / Ets1 protein, mouse; 0 / Gene Products, rex; 0 / Gene Products, tax; 0 / Parathyroid Hormone-Related Protein; 0 / Proto-Oncogene Protein c-ets-1; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-ets; 0 / RNA, Messenger; 0 / Receptors, Antigen, T-Cell; 0 / Transcription Factors; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases
  • [Other-IDs] NLM/ NIHMS94146; NLM/ PMC2661941
  •  go-up   go-down


80. Casper C, Wald A: The use of antiviral drugs in the prevention and treatment of Kaposi sarcoma, multicentric Castleman disease and primary effusion lymphoma. Curr Top Microbiol Immunol; 2007;312:289-307
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kaposi sarcoma-associated herpesvirus [KSHV, also known as human herpesvirus 8 (HHV-8)] is the most recently identified member of the human herpesvirus family.
  • Kaposi sarcoma (KS), primary effusion lymphoma, and multicentric Castleman disease are all associated with KSHV infection.
  • Although the incidence of KS has declined dramatically in areas with access to highly active antiretroviral therapy, it remains the most common AIDS-associated malignancy in the developed world and is one of the most common cancers in developing nations.
  • Current treatment options for KSHV-associated disease are ineffective, unavailable, or toxic to many affected persons.
  • A growing body of basic science, preclinical, and observational data suggests that antiviral medications may play an important role in the prevention and treatment of KSHV-associated disease.
  • [MeSH-major] Antiviral Agents / therapeutic use. Giant Lymph Node Hyperplasia / drug therapy. Lymphoma, AIDS-Related / drug therapy. Sarcoma, Kaposi / prevention & control
  • [MeSH-minor] Animals. Anti-HIV Agents / therapeutic use. Antiretroviral Therapy, Highly Active. DNA Replication / drug effects. Disease Models, Animal. Humans. Pleural Effusion, Malignant / drug therapy

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17089802.001).
  • [ISSN] 0070-217X
  • [Journal-full-title] Current topics in microbiology and immunology
  • [ISO-abbreviation] Curr. Top. Microbiol. Immunol.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / K23 AI054162; United States / NIAID NIH HHS / AI / U19 AI31448
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Antiviral Agents
  • [Number-of-references] 72
  •  go-up   go-down


81. Herbeck JT, Gottlieb GS, Winkler CA, Nelson GW, An P, Maust BS, Wong KG, Troyer JL, Goedert JJ, Kessing BD, Detels R, Wolinsky SM, Martinson J, Buchbinder S, Kirk GD, Jacobson LP, Margolick JB, Kaslow RA, O'Brien SJ, Mullins JI: Multistage genomewide association study identifies a locus at 1q41 associated with rate of HIV-1 disease progression to clinical AIDS. J Infect Dis; 2010 Feb 15;201(4):618-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multistage genomewide association study identifies a locus at 1q41 associated with rate of HIV-1 disease progression to clinical AIDS.
  • BACKGROUND: A mean of 9-10 years of human immunodeficiency virus type 1 (HIV-1) infection elapse before clinical AIDS develops in untreated persons, but this rate of disease progression varies substantially among individuals.
  • To investigate host genetic determinants of the rate of progression to clinical AIDS, we performed a multistage genomewide association study.
  • METHODS: The discovery stage comprised 156 individuals from the Multicenter AIDS Cohort Study, enriched with rapid and long-term nonprogressors to increase statistical power.
  • This was followed by replication tests of putatively associated genotypes in an independent population of 590 HIV-1-infected seroconverters.
  • RESULTS: Significant associations with delayed AIDS progression were observed in a haplotype located at 1q41, 36 kb upstream of PROX1 on chromosome 1 (relative hazard ratio, 0.69; Fisher's combined P = 6.23 X 10(-7)).
  • CONCLUSIONS: This study identified and replicated a locus upstream of PROX1 that is associated with delayed progression to clinical AIDS.
  • PROX1 is a negative regulator of interferon-gamma expression in T cells and also mitigates the advancement of vascular neoplasms, such as Kaposi sarcoma, a common AIDS-defining malignancy.
  • This study adds to the cumulative polygenic host component that effectively regulates the progression to clinical AIDS among HIV-1-infected individuals, raising prospects for potential new avenues for therapy and improvements in AIDS prognosis.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 1999 Jun 1;162(11):6942-6 [10352317.001]
  • [Cites] Science. 1996 Sep 27;273(5283):1856-62 [8791590.001]
  • [Cites] Nat Genet. 2006 Aug;38(8):904-9 [16862161.001]
  • [Cites] Annu Rev Med. 2003;54:535-51 [12525683.001]
  • [Cites] Nat Genet. 2004 Jun;36(6):565-74 [15167933.001]
  • [Cites] BMC Bioinformatics. 2008 Aug 12;9 Suppl 9:S17 [18793462.001]
  • [Cites] Nucleic Acids Res. 2007 Jan;35(Database issue):D610-7 [17148474.001]
  • [Cites] PLoS One. 2009;4(9):e6915 [19730697.001]
  • [Cites] Ann Intern Med. 2001 Nov 6;135(9):782-95 [11694103.001]
  • [Cites] Am J Epidemiol. 1987 Aug;126(2):310-8 [3300281.001]
  • [Cites] Science. 1996 May 24;272(5265):1167-70 [8638160.001]
  • [Cites] J Invest Dermatol. 2008 Dec;128(12):2798-806 [18580962.001]
  • [Cites] Bioinformatics. 2005 Jan 15;21(2):263-5 [15297300.001]
  • [Cites] JAMA. 2007 Jun 6;297(21):2349-50 [17551128.001]
  • [Cites] N Engl J Med. 1989 Oct 26;321(17):1141-8 [2477702.001]
  • [Cites] AIDS. 1994 Aug;8(8):1123-8 [7986410.001]
  • [Cites] Behav Genet. 2000 Mar;30(2):141-6 [10979604.001]
  • [Cites] JAMA. 1998 Jan 7;279(1):35-40 [9424041.001]
  • [Cites] MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19 [1361652.001]
  • [Cites] Ann Intern Med. 1995 Apr 15;122(8):573-9 [7887550.001]
  • [Cites] AIDS. 1997;11 Suppl A:S69-76 [9451969.001]
  • [Cites] Am J Hum Genet. 2007 Sep;81(3):559-75 [17701901.001]
  • [Cites] Nature. 2007 Jun 7;447(7145):655-60 [17554299.001]
  • [Cites] Lancet. 1997 Mar 29;349(9056):922-3 [9093257.001]
  • [Cites] Cell Res. 2008 Sep;18(9):911-20 [19160541.001]
  • [Cites] Science. 2007 Aug 17;317(5840):944-7 [17641165.001]
  • [Cites] Genome Res. 2008 Apr;18(4):640-3 [18256235.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2709-14 [10694578.001]
  • [Cites] Am J Hum Genet. 2007 Mar;80(3):567-76 [17273979.001]
  • [Cites] Annu Rev Genet. 2000;34:563-591 [11092839.001]
  • [Cites] J Infect Dis. 2009 Feb 1;199(3):419-26 [19115949.001]
  • [Cites] Nat Med. 1996 Apr;2(4):405-11 [8597949.001]
  • (PMID = 20064070.001).
  • [ISSN] 1537-6613
  • [Journal-full-title] The Journal of infectious diseases
  • [ISO-abbreviation] J. Infect. Dis.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / U01 AI035042; United States / NIAID NIH HHS / AI / U01 AI35043; United States / NIAID NIH HHS / AI / U01 AI037984; United States / NIDA NIH HHS / DA / R56 DA004334; United States / NIDA NIH HHS / DA / R01-DA04334; United States / NIAID NIH HHS / AI / U01 AI37984; United States / NIAID NIH HHS / AI / U01 AI035042-10; United States / NIAID NIH HHS / AI / R37 AI047734-06A1; United States / NIAID NIH HHS / AI / T32 AI007140; United States / NIDA NIH HHS / DA / R01 DA004334; United States / PHS HHS / / R01-1258; United States / NIAID NIH HHS / AI / P30 AI27757; United States / NIAID NIH HHS / AI / U01 AI35040; United States / NCRR NIH HHS / RR / 5M01 RR00722; United States / NIAID NIH HHS / AI / P30 AI027757-169012; United States / NIAID NIH HHS / AI / P30 AI027757-21; United States / NIAID NIH HHS / AI / U01 AI037613; United States / NIAID NIH HHS / AI / T32 AI07140; United States / NIAID NIH HHS / AI / U01 AI037984-04; United States / NIAID NIH HHS / AI / P30 AI027757-119010; United States / NCRR NIH HHS / RR / M01 RR000722; United States / NIAID NIH HHS / AI / U01 AI035041; United States / Intramural NIH HHS / / ; United States / NIAID NIH HHS / AI / U01 AI35041; United States / NIAID NIH HHS / AI / R37 AI047734; United States / NIAID NIH HHS / AI / P01 AI057005; United States / NIAID NIH HHS / AI / R37 AI47734; United States / NIAID NIH HHS / AI / U01 AI035043; United States / NIAID NIH HHS / AI / P30 AI027757; United States / NIAID NIH HHS / AI / P30 AI027757-219021; United States / NIAID NIH HHS / AI / U01 AI35042; United States / PHS HHS / / U64/CCU900523-08; United States / NIAID NIH HHS / AI / U01 AI035040; United States / NIAID NIH HHS / AI / U01 AI35039; United States / NIAID NIH HHS / AI / U01 AI035040-18; United States / NIAID NIH HHS / AI / U01 AI035039; United States / NIAID NIH HHS / AI / U01 AI37613
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Tumor Suppressor Proteins; 0 / prospero-related homeobox 1 protein
  • [Other-IDs] NLM/ NIHMS174410; NLM/ PMC2928718
  •  go-up   go-down


82. Subirá D, Górgolas M, Castañón S, Serrano C, Román A, Rivas F, Tomás JF: Advantages of flow cytometry immunophenotyping for the diagnosis of central nervous system non-Hodgkin's lymphoma in AIDS patients. HIV Med; 2005 Jan;6(1):21-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advantages of flow cytometry immunophenotyping for the diagnosis of central nervous system non-Hodgkin's lymphoma in AIDS patients.
  • The description of an aberrant immunophenotype was the criterion used to define the malignant nature of any CSF cell population.
  • RESULTS: FCI and cytology gave concordant results for 48 of the 56 CSF samples studied: 37 were negative for malignancy and 11 had evidence of CNS lymphoma.
  • Discordant results were obtained for eight CSF samples, and the accuracy of the FCI findings could be demonstrated for four CSF samples described as positive for malignancy according to the FCI criteria.
  • CONCLUSIONS: A high level of agreement was found between the results obtained using the two methods, but FCI gave at least 25% higher sensitivity than conventional cytomorphological methods for the detection of malignant cells.
  • [MeSH-major] Lymphoma, AIDS-Related / diagnosis. Meningeal Neoplasms / diagnosis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15670248.001).
  • [ISSN] 1464-2662
  • [Journal-full-title] HIV medicine
  • [ISO-abbreviation] HIV Med.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


83. Vazquez JA, Schranz JA, Clark K, Goldstein BP, Reboli A, Fichtenbaum C: A phase 2, open-label study of the safety and efficacy of intravenous anidulafungin as a treatment for azole-refractory mucosal candidiasis. J Acquir Immune Defic Syndr; 2008 Jul 1;48(3):304-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Azole-refractory mucosal candidiasis is a debilitating disease frequently seen in patients who are immunosuppressed as a result of HIV, malignancy, posttransplant immunosuppressive therapy, persistent neutropenia, steroid use, or diabetes.
  • [MeSH-major] AIDS-Related Opportunistic Infections / drug therapy. Antifungal Agents / therapeutic use. Candidiasis / drug therapy. Candidiasis, Oral / drug therapy. Echinocandins / therapeutic use. Esophageal Diseases / drug therapy. Mucous Membrane


84. Noguchi K, Fukazawa H, Murakami Y, Takahashi N, Yamagoe S, Uehara Y: Gamma-herpesviruses and cellular signaling in AIDS-associated malignancies. Cancer Sci; 2007 Sep;98(9):1288-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gamma-herpesviruses and cellular signaling in AIDS-associated malignancies.
  • gamma-Herpesviruses, Epstein-Barr virus (EBV/HHV-4) and Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8), are involved in human carcinogenesis, particularly in immunocompromised patients.
  • Virus-associated malignancies are becoming of significant concern for the mortality of long-lived immunocompromised patients, and therefore, research of advanced strategies for AIDS-related malignancies is an important field in cancer chemotherapy.
  • Detailed understanding of the EBV and KSHV lifecycle and related cancers at the molecular level is required for novel strategies of molecular-targeted cancer chemotherapy.
  • The present review gives a simple outline of the functional interactions between KSHV- and EBV-viral gene products and host cell deregulated signaling pathways as possible targets of chemotherapy against AIDS-related malignancies.
  • [MeSH-major] Herpesvirus 4, Human / pathogenicity. Herpesvirus 8, Human / pathogenicity. Lymphoma, AIDS-Related / metabolism. Lymphoma, AIDS-Related / virology. Sarcoma, Kaposi / metabolism. Sarcoma, Kaposi / virology. Signal Transduction / physiology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17640300.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 102
  •  go-up   go-down


85. Greene W, Kuhne K, Ye F, Chen J, Zhou F, Lei X, Gao SJ: Molecular biology of KSHV in relation to AIDS-associated oncogenesis. Cancer Treat Res; 2007;133:69-127
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular biology of KSHV in relation to AIDS-associated oncogenesis.
  • KSHV has been established as the causative agent of KS, PEL, and MCD, malignancies occurring more frequently in AIDS patients.
  • KSHV latent infection and lytic reactivation are characterized by distinct gene expression profiles, and both latency and lytic reactivation seem to be required for malignant progression.
  • As a sophisticated oncogenic virus, KSHV has evolved to possess a formidable repertoire of potent mechanisms that enable it to target and manipulate host cell pathways, leading to increased cell proliferation, increased cell survival, dysregulated angiogenesis, evasion of immunity, and malignant progression in the immunocompromised host.
  • The complex interplay between the two viruses dramatically elevates the risk for development of KSHV-induced malignancies, KS, PEL, and MCD.
  • In fact, clinically significant immune deficiency is not necessary for the induction of KSHV-related malignancy.
  • Because of variables such as lack of access to therapy noncompliance with prescribed treatment, failure to respond to treatment and the development of drug-resistant strains of HIV, KSHV-induced malignancies will continue to present as major health concerns.